roche annual report business report part innovate healthcareroche business report survey annual report informs roches financial operating results well companys strategic direction longer term value opinion reader ofour reportswe want find readers think annual reportin particular business report part please click link fill online questionnaire allthis take five minutes opinion help us improve business report next year youll find questionnaire httpwwwrochebusinessreportsurveycom thank much support make difference every completed questionnaire receivedroche donate swiss francs reactan independent foundation pools roche employeesinitiatives skills support selected charitable projects organisations company designate survey response donations react support phelophepaa mobile health train serving rural villages throughout south africaphelophepa sees av erage ofover patients year among many previously access basic health care completed questionnaire thus help provide funding expertise sustainable work south africainnovation spanning entire healthcare spectrum pharmaceuticals diagnostics company roche brings pioneering products services market every stage healthcare process identifying disease susceptibilities testing disease atrisk populations prevention diagnosis therapy treatment monitoring focus products deliver significant benefits patients health professionals core element business strategy one key reasons success researchintensive company longterm strategic focus roche strives deliver sustainable value stakeholderspredisposition table contents information predisposition todisease offers huge potential business report butweve got long way go key figures year brief letter chairman roche group early detection group results outlook ifi hadnt determined group strategy tofind heri might notbe alive today tell story pharmaceuticals pharmaceuticals division brief results therapeutic areas research development prevention rd pipeline little brother caught flu diagnostics still got go holidays diagnostics division brief results business areas research development key product launches scheduled diagnosis corporate governance remuneration report ifmy doctor hadnt thought ofit corporate governance id never known hep c remuneration report creating sustainable value management approach key management topics therapy people ive got life back children got communities father back safety health environmental protection assurance monitoring gri statement roche global market presence monitor blood glucose every day go hospital month business report key figures roche group index sales mchf equity ratio research development mchf total employee remuneration mchf operating profit exceptional items mchf dividend mchf income taxes mchf number employees profit continuing businesses mchf patients participating clinical trials core earnings per share chf ecoefficiency rate index index price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased continuing businesses figures annual report key figures indexed full index global reporting initiative gri indicators proposed board directors used report see wwwrochecomsusgri development phases iv calculation ecoefficiency rate see wwwrochecomsussheperformance business report year brief group group sales advance billion swiss francs record increase billion swiss francs operating profit margin increases percentage points net income billion swiss francs driven strong operating performance significantly higher net financial income board propose th consecutive dividend increase swiss francs per share nonvoting equity security pharmaceuticals pharmaceutical sales grow three times fast global market division reinforces leadership oncology operating profit margin rises percentage points marketing approvals received avastin lung cancer herceptin early stage breast cancer mabtherarituxan rheumatoid arthritis first marketing applications filed mircera renal anemia major development targets met new marketing applications filed approvals received diagnostics division posts sales growth consolidating global market leadership anticipated divisional operating profit declines result investments new product launches impairment charges intangible assets lower royalty income licences molecular diagnostics segment new range accuchek blood glucose monitoring products available worldwide outlook doubledigit sales growth roche group pharmaceuticals division abovemarket sales growth divisions core earnings per share growth target line sales growth additional information roche visit httpwwwrochecom growth rates based local currencies operating profits operating profit margins stated exceptional items business report business report letter chairman another year strong growth exceptional items increased local cur outstanding financial performance roche rencies billion swiss francs groups groups sales rose local currencies record operating profit margin increased furtherto high billion swiss francsthis billion swiss timewe invested divisions franc revenue increase reflects organic rich research development pipelines also growth topline growth driven primarily increased spending launch activities con pharmaceuticals divisionwhere sales advanced struction ofnew biotech manufacturing facilities three times market growth rate roche diagnostics maintained leadership net financial income also significantly position increasingly competitive market compared total net income rose one thanks numerous new product launches third billion swiss francs highest profit continued growth divisions business ever recorded roche core earnings per share areas core eps rose groups earnings performance improved sig board directors propose divi nificantly last year operating profit dend increased swiss business report letter chairman francs per share nonvoting equity security roches strategy remains firmly focused pre swiss francs subject scription medicines modern diagnosticswith approval annual general meeting share increased financial strength holdersthis th consecutive dividend resources targeted businessbuilding invest increase ments ofthese core businessesdeveloping healthcare innovations products services rep indicated beforethe pharmaceuticals division resenting real advances fight serious main driver behind groups excellent diseases important thing roche results sales exceeded billion swiss mission change francs increase local currencies research development activities aimed market averaged growth last year extending patientslives improving health robust increase driven primarily sus quality oflifeworldwidewe spend million tained strong demand cancer medicines swiss francs every day pursuit oftheseobjectives continued government stockpiling anti last year rd expenditure pharmaceuticals influenza drug tamiflu sales ofbonvivaboniva division amounted sales absolute osteoporosis oncology transplantation figurestotal rd expenditure group rose virology currently three leading therapeutic well billion swiss francs making franchises importantly sales cancer roche one researchintensive compa medicines surged approximately billion nies industry swiss francsand account half divi sions total revenuesfor first timethe pharma plan intensify cooperation ceuticals divisions operating profit excep pharmaceuticals diagnostics divisions tional items exceeded billion swiss francsand major therapeutic areas order deliver operating profit margin rose significantlyto products tailored needs specific patient populations benefits precise diag diagnostics division posted sales billion noses better targeted treatments already swiss francsa increase local currencies evident particularly oncology tighter cross previous year slow start sales growth divisional linkages researchdevelop accelerated slightly market growth rate ment marketing organisations strengthen second half year helped roll ability actively shape future oftherapeu new products divisions tics diagnostics centralized diagnostics business particularly immunodiagnostics portfolio main con roche reselected inclusion dow tributor growth new portfolio jones sustainability indexes ftsegood accuchek blood glucose monitoring products index series recognition efforts marketwe expect roche diabetes care balance corporate responsibility business return abovemarket growth well divi objectives core mission innovate healthcare sional operating profit exceptional items believe making sustainability integral declined local currencies approximately part business model operations fosters billion swiss francsthe decrease primarily innovation minimises business risks creates due higher costs new product launches value stakeholders ongoing pricing pressure divisions markets operating profit also impacted impairment final analysisof courseit roches people charges intangible assets relating dise made prosperousinnovative com tronic acquisition pany todaythanks untiring dedication business report letter chairman professionalism roche able bring prod ucts services market make real differ ence patientslives strong businesses con tinued create new jobs last yearin total number roche employees worldwide increased would like take additional opportunity thank roche groups employees tremendous job continue tough challenging marketplacethe awards received last year outstanding com pany work special source ofpride ofus roche without innovation medical progress access quality healthcare unsustainable reasonit vital raise awareness role pricing patent protection play industrys ability innovateroche continue actively engage policymakers public issues tomorrows healthcare market offer enormous opportunities pose enormous challenges roche pursue opportunities tackle challenges confidence position strengthwith strategy focused innovation portfolio new productswe well equipped sustained growthin expect groups pharmaceu ticals divisions sales grow doubledigit rates local currenciesand expect see continued abovemarket sales growth divisions aiming core eps increase line group sales franz bhumer business report information predisposition disease offers huge potential weve got long way go business report predisposition testing holds promise predictive preventative medicine identifying individuals risk complex diseases isstill challengewhile technologies genetic testing pcr microarrays available identifying right prognostic markers straightforward taskhenry erlichvp research director human genetics roche molecular diagnostics leftin main pictureis good position knowas internationally recognised expert genetic factors associated disease many contacts theglobal research community estimating risk diseases already standard clinical practicesuch measuring blood pressure cholesterol risk factors stroke heart attackgenetic predisposition testing canbecome part clinical practicesays erlich buta number challenges met firstand need aglobalinterdisciplinary effort researchers around world already begun addressing challengesaccording erlich predisposition testing couldaid designing clinical trials understanding natural course diseaseinmany casesthe genetic markers might oneday alsohelp clinicians select besttherapythey might even point way new discoveries would allow doctors prevent disease occurring predisposed individual predisposition must predisposition markers predictive disease effective preventive measures must also available exam ple statins blood pressure medications routinely pre scribed reduce risk cardiovascular disease individuals elevated risk similarly osteoporosis medicines could pre scribed predisposed individuals lost signifi cant bone mass preventive measures could reduce public health burden disease expand market effective medicines business report roche group group results divisions operating profit margin declined percentage points mar operationally financially another gin decrease primarily due investments outstanding year roche group total sales rollout ofnew productsimpairment charges increased significantlyrising local curren intangible assets lower royalty income cies swiss francs billion swiss licences francs billion swiss franc increase revenues organic growthsales contin groups strong profitability also reflected ued grow especially strongly pharmaceuti key indicators ebitda rose billion cals divisionits sales increased year swiss francs billion swiss francs local currencies swiss francsor three times global market growth rate led net financial income totalled million swiss strong demand cancer medicines herceptin francsup significantly million swiss avastin mabtherarituxanthe antiinfluenza francs recorded effective tax rate medicine tamifluand bonvivabonivafor osteo compared porosisas resultroche extended market lead ership oncologytransplantation virologyin group net income rose billion swiss diagnostics division sales increased local francsto billion swiss francsand groups currencies swiss francs billion swiss return sales margin increased percentage francswith centralized diagnostics unit mak points net income attributable roche ing largest contribution growthdiagnostics shareholders higher year sales accelerated grew slightly core earnings per share core eps rose ahead ofthe market year whole groups balance sheet thus strengthened ratio equity total assets robust increase group sales last year ofassets financed longterm positive impact earnings perform ance groups operating profit excep tional items increased local currencies outlook billion swiss francsthe corresponding oper ating profit margin rose percentage points barring unforeseen events roche anticipates fur sales growth offset ther positive growth expect groups increased investments roches strong develop pharmaceuticals divisions sales con ment pipeline new product launches tinue togrow doubledigit rates local curren ciesinboth pharmaceuticals division groups improved earnings performance diagnostics divisionroche anticipates continued primarily due significantly higher profit con abovemarket sales growth local currencies tributed pharmaceuticals divisionthe divi roches target core eps grow line sions operating profit exceptional items group sales despite significant investments increased local currencies billion researchdevelopmentproduction marketing swiss francsresulting margin improve ment percentage points diagnostics division posted operating earnings exceptional items financial profit billion swiss francsdown local income financing costs tax depreciation amortisa currencies high divisional profit recorded tion including impairment business report roche group group strategy another trend fuelling demand highquality healthcare patient empowerment many people trends market today better informed health issues medical advances used worlds population growing standably therefore demanding greater larger older ever greater numbers people say decisions affecting care affected diseases ageing many cancers want access latest medical procedures alzheimers disease diabetes rheumatoid medicines arthritis example already becoming prevalent making urgent find health systems everywhere financially effective ways treating growing stretchedhow demands satisfied ageing populationpeople going need healthcare still kept affordable better healthcarenot ofthe pioneer personalised medicine healthcare things one size fit genes countless environmen tal factors influence outcomes treat ments receive including response medicines moreover many diseases occur genetically distinct subtypes vary clinical course prognosis thus two patients seemingly disease treated medicine may respond radically different ways one may benefit treatment experi ences unwanted side effects without clinical benefit fight hivaids hepatitis c doctors routinely perform viral load tests guide treat roche committed providing healthcare pro ment selection track patients responses treatment fessionals powerful diagnostic tools make dosing adjustments necessary targeted treatments based sciences increasing understanding diseases arise molecular tests also play key role development level one approach promises steady new antiviral drugs similar successes achieved improvements therapeutic options available oncology rheumatology says dr tim jaeger patients using innovative diagnostic technologies pictured heads drive personalised health physicians increasingly able identify patient care initiative roche diagnostics pharma populations likely benefit particular ceuticals divisions working together example treatments better ways detecting differentiating certain cancers exploiting new mechanisms drug recent years roche provided examples action provide specific groups patients linking diagnostic pharmaceutical knowledge effective targeted treatments projects like make lead personalised healthcare roche pioneer improving patient care ultimately great deal toease pressure stretched healthcare budgets business report roche group group innovation network majority shareholdings alliances licensing agreements spinoffs medical progress essential providing sustain prioritise areas significant unmet need able access highquality care point expertise make difference areas governments payers agree stay like oncology virology diabetes inflammatory competitive todays increasingly costsensitive andmetabolic disorders diseases ofthe central marketresearchbased healthcare companies like nervous system aim leader roche need develop products health eco areas interest today roche nomic well clinical benefits medicines market leader highgrowth therapeutic areas extend patients lives improve quality life oncology transplantation hepatitis fewer side effects offer bothand world leader molecular centralized diagnostic tests reduce treatment costs diagnostics diabetes management helping physicians choose appropriate therapies patients first time around worldclass rd backbone strategy diagnostics account healthcare spent well billion swiss francs spendingyet timelyaccurate diagnostic informa coming years tion required roughly clinical continue increase rd budget selected decisions areas opportunityour innovation model relies cuttingedge drug diagnostics clinically differentiated products create value research global collaborative rd network stakeholders roche majority shareholder genentech united states chugai japan roche prime strategic focus innova companies operate largely independently tion strive develop clinically differentiated believe encourages greater diversity solutions medical needs yet approaches increasing chances success adequately addressed creates value additionthe groups research capabilities stakeholdersfrom patientsto providersto health augmented host scientific commercial care systems wholewe devote resources collaborations external biotech companies two researchintensive businessespharmaceuti universities research organisations around cals diagnostics within businesses world business report roche group recognise innovation requires perseverence longterm perspectivewe invest early new technologies judge critical longterm viability strength develop ment pipelineroche one first pharma ceutical companies enter biotech arena establishing relationship genentech early becoming majority share holder time molecular research still infancy around time acquired worldwide rights polymerase chain reaction pcr technological advance molecular biology developed diagnostic products continue set new stan dards speed accuracy today biopharma ceuticals account half group salesand roche global market leader molecular diagnostics biotechnology opened completely new approaches diagnosing treating diseasepar ticularly cancer development portfolio cur rently includes therapeutic proteins developed total indications investing heavily new manufacturing facilities meet growing demand bio therapeutics biodiagnostics emerging field personalised medicine tremendous potential make healthcare better safer costeffectivewith combined strengths diagnostics therapeutics equipped take lead realising potential see pioneer personalised medicinep pharmaceuticals research network strengths biotechnology leadership diagnostics rd competitive advantages ina changing marketplace believe deliver greater value innovation strategy selling metoo products generics overthecounter remedies economic well clinical benefitstargeted therapies diagnostic tests support better medical decisionmaking likely approved regulators accepted patients covered reimbursed payersour goal deliver innovations benefit health care stakeholdersand thats change business report hadnt determined find might alive today tell story business report finding cancer types helps patients get right treatment donna rullofrom northwest victoria australiawas first treated early breast cancer insomething doctor said stood yourcancer herpositivedonna immediately started gathering information determined find meant outlook treatment options donna learned herpositive tumours particularly aggressivegrow fast likelyto relapseher search information ledherto richard bellhead cancer care geelong hospitalhe enrolled donna clinical trial investigating effectiveness herceptin trastuzumab early herpositive breast cancerherceptin specifically designed treat herpositive tumours breast cancer isnt single diseaseits stage type factors influence treatment decisions expected outcomesexplains profbell thecancer detected early treatment tailored thespecific tumour patient characteristics better outcomes achievedi cant stress enough important determine aspects type breast cancer early possible optimise treatment planning donnas case early identification breast cancer herpositive targeted treatment herceptin paid stayed remission early detection important early diagnosis breast cancer fast iden tification tumour type help doctors estimate quickly cancer grow respond spe cific treatments example knowing breast cancer patients status diagnosis enables doctors select effective treatment programme increasing patients chances survival business report pharmaceuticals division brief sales millions chf operating profit exceptional items millions chf published annual report number employees key figures change change millions chf chf local currencies sales sales roche pharmaceuticals genentech chugai ebitda operating profit research development exceptional items pharma executive committee january william burns ceo division roche pharmaceuticals george b abercrombie north america jennifer allerton informatics jeanjacques garaud development eduard holdener chief medical officer peter hug partnering jonathan kc knowles research dominic p moorhead finance controlling paul newtonsyms human resources claude schreiner western europe pascal soriot commercial operations jan van koeveringe technical operations business report pharmaceuticals division sales region roche groups pharmaceuticals division made ofroche pharmaceuticalsrepresented latin america countriesand majority shareholdings japan genentech united states chugai others japan roche cooperates closely genentech chugai also maintains licensing collaborative agreements companies europe around world giving roche group wide north america access promising experimental medicines cuttingedge technologies italics growth rates results strong sales growth combined pro ductivity improvements particularly manu pharmaceuticals division set new records facturing factors outweighed sales full year rose local cur significantly higher investments marketing rencies swiss francs us dollars distribution research development billion swiss francs billion francs ebitda totalled billion francs three times global market salescompared growth rate roche outperformed global pharmaceuticals market every quarter last four years regional sales growth sig therapeutic areas nificantly outpaced market average north america vs europe vs oncology japan sales declined line market average due governmentmandated price cuts roche group worlds leading provider healthcare reimbursement changes cancer medicines mabtherarituxan herceptinavastinxeloda tarcevathe group overall growth driven primarily strong currently markets five innovative cancer treatments demand divisions key oncology products shown significantly extend patient influenza medicine tamiflu genentechs survivalwe continuing investigate new uses ophthalmology drug lucentisand osteoporosis effective combinations groups medicine bonvivaboniva anticancer products extensive development programme see major development activitiesp divisions operating profit exceptional items advanced billion swiss francs operating margin percentage points unless otherwise stated growth rates local cur tothe margin increase result ofthe rencies business report pharmaceuticals sales therapeutic area known herpositive accounts breast cancers worldwide sales theproduct nearly doubled addition strong uptake medical community growth respiratory diseases driven mainly reimbursement approvals metabolic diseases euthe us key markets wider use bone diseases product surgery earlystage breast central nervous system cancer approvals based clinical trial infectious diseases results showing setting herceptin cardiovascular diseases reduce risk cancer recurrence inflammatory risk death thirdin october autoimmune diseases roche filed application eu authorities transplantation approval ofherceptin combined hormonal virology therapy treat advanced metastatic breast cancer ophthalmology na hormone receptorpositive others positivein november chugai filed application renal anemia japanese ministry healthlabour oncology welfare mhlw seeking expansion pro italics growth rates ducts marketing licence include operable early stage herpositive breast cancer sales roche groups oncology portfolio grew account information roche clinical trials visit roche pharmaceutical sales clinical trial registry wwwrochetrialscom see also roches clinical trial protocol registry trial results sales mabtherarituxan rituximab database p report treatment indolent aggressive forms nonhodgkins lymphoma nhl continued avastin bevacizumab first targeted anti advance strongly throughout growth angiogenic therapy demonstrated patient supported increased use product survival benefits four major tumour types firstline treatment forms disease metastatic colorectal breast lung cancer particularly europe emerging markets also advanced kidney cancer avastin russia latin americahigh treatment rates inhibits growth blood vessels tumours rituxan us maintained thus cutting blood supply tumours need yearin july roche received eu regulatory grow spread launched approval market mabthera maintenance markets worldwide firstline treatment therapy relapsed refractory follicular nhl advanced metastatic colorectal cancer crc common form indolent nhl sales grew strongly expected us genentech received marketing approvals increase driven continuing market three additional indications rituxanincluding uptakeroche preparing ask eu authorities treatment previously untreated follicular lym widen products current marketing approval phoma metastatic crc include combinations chemotherapy regimens based xeloda oxali herceptin trastuzumab designed specifically platin filing planned first half treat particularly aggressive form tumour based data largestever clinical trial firstline metastatic crc showing adding avastin chemotherapy folfox xelox significantly improves progressionfree oncology portfolio mabtherarituxan herceptin avastin xeloda tarceva bondronat kytril furtulon neupogen survival compared chemotherapy alone neorecormon roferona neutrogin picibanil april chugai filed first marketing application vesanoid avastin japanfor treatment ofadvanced business report pharmaceuticals cancer one disease worlds leading provider cancer estimated million new cases annually lung medicines roche group working hard cancer common form cancer worldwide help meet enormous need new treatment leading cause cancer deaths world andin options targeted therapies europe nonsmall cell lung cancer isthe common form lung cancer accounting approximately cancer abnormal growth cells proliferate cases tarceva avastin uncontrolled cell division malignant cells may invade tissues spread metasta year people worldwide diag sise distant parts body cancer nosed kidney cancer die one disease group distinct disease rates expected increase kidney disorders one main causes death cancer common men incidence industrialised countries increases age renal cell carcinoma accounts kidney cancers avastin roferona nonhodgkins lymphoma group cancers affect lymphatic system grown inci pancreatic cancer particularly aggressive disease dence since early class extremely difficult treat often resistant cancercurrently affects million people world chemotherapy radiotherapy tends spread wide mabtherarituxan quickly parts body kills higher pro portion patients first year diagnosis colorectal cancer cancer large intestine cancer fifth leading cause cancer rectum accounts million new cases around deaths developed world pancreatic cancer newly diagnosed cancers worldwide claims lives people every year tarceva year second common cause cancer xeloda deaths europe main treatment surgery may also combined radiotherapy stomach cancer accounts close million new chemotherapy avastin xeloda cases least deaths year making second common type cancer breast cancer common cancer among secondlargest cause cancer deaths worldwide women worldwide million women newly main type cancer seen china korea diagnosed dying disease japan cases occur xeloda year different types breast cancer knowledge tumour characteristics important information visit treatment decisions herceptin xeloda avastin httpwwwrochecomdiseaseshtm recurrent colorectal cancerthe application filing indication submitted filed early mhlw initiative aimed eus european medicines agency emea expediting patient access innovative medicines august addition roche filed application already approved usor euand july eu marketing authorisation avastin also given priority review status treatment advanced breast cancer september fda asked genentech provide octoberfollowing priority reviewthe us food additional data analysis support us applica drug administration fda approved avastin tion approval avastin treat metastatic treatment nonsmall cell lung cancer breast cancergenentech agreed supply nsclc common form disease additional data mid business report pharmaceuticals topselling pharmaceutical products roche group sales change product generic name indication millions chf local currencies mabtherarituxan rituximab nonhodgkins lymphoma rheumatoid arthritis herceptin trastuzumab metastatic breast cancer adjuvant breast cancer avastin bevacizumab metastatic colorectal cancer advanced nonsmall cell lung cancer tamiflu oseltamivir treatment prevention influenza b neorecormon epogin epoetin beta anemia cellcept mycophenolate mofetil transplantation pegasys peginterferon alfaa hepatitis b c xeloda capecitabine colorectal cancer breast cancer tarceva erlotinib nonsmall cell lung cancer advanced pancreatic cancer xenical orlistat weight loss weight control xolair omalizumab asthma kytril granisetron nausea vomiting induced chemotherapy radiation therapy following surgery nutropin somatropin growth hormone deficiency bonvivaboniva ibandronic acid osteoporosis valcyte cymevene valganciclovir ganciclovir cytomegalovirus infection lucentis ranibizumab wet agerelated macular degeneration pulmozyme dornase alfadnase cystic fibrosis rocephin ceftriaxone bacterial infections neutrogin lenograstim neutropenia associated chemotherapy activase tnkase alteplase tenecteplase acute myocardial infarction heart attack jointly marketed genentech novartis interim analysis major phase iii trial metastatic breast colorectal cancermarketing avoren released december shown applications planned worldwideexcept japan avastin also effective fourth type cancer first half approval com significantly improves progressionfree survival bination xeloda oxaliplatin avastin given firstline treatment advanced metastatic colorectal cancer filings renal cell carcinoma results form based results two phase iii studies com basis supplemental eu marketing application pleted planned july roche filed eu marketing application xeloda capecitabine effective oral anticancer approval xeloda combination therapy greatly simplifies treatment also cisplatin treatment stomach cancer saves costs reducing need hospital visits filing based results phase iii strong sales growth fuelled mainly comparative study efficacy safety increased use product adjuvant treat combined xeloda cisplatin versus current ment ofcolon cancer us europexeloda standard therapy currently also approved treatment business report pharmaceuticals major product approvals product generic name indication dosage form country avastin bevacizumab secondline metastatic colorectal cancer usa combination fubased chemotherapy firstline nonsmall cell lung cancer usa bonvivaboniva injection ibandronic acid osteoporosis intravenous formulation usa eu switzerland copegus ribavirin chronic hepatitis c combination pegasys japan epogin epoetin beta anemia premature infants japan femara letrozole breast cancer postmenopausal women japan herceptin trastuzumab adjuvant earlystage herpositive breast cancer usa eu switzerland invirase saquinavir hiv disease mg tablet japan lucentis ranibizumab wet agerelated macular degeneration usa mabtherarituxan rituximab rheumatoid arthritis antitnf failures usa eu switzerland firstline treatment diffuse large bcell cdpositive usa nonhodgkins lymphoma nhl firstline treatment patients follicular nhl usa combination cvp chemotherapy maintenance therapy patients relapsed eu refractory follicular nhl switzerland treatment lowgrade nhl following firstline usa treatment cvp chemotherapy neorecormon epoetin beta onceweekly treatment anemia patients solid eu tumours receiving chemotherapy iu prefilled syringe tamiflu oseltamivir pediatric influenza prophylaxis eu switzerland tarceva erlotinib metastatic pancreatic cancer combination gemcitabine eu includes supplemental indications updated january jointly marketed chugai novartis jointly marketed genentech novartis two years since launch sales usage anemia tarceva erlotiniba targeted drug proven survival benefit advanced nonsmall cell lung anemia occurs number ofred blood cells cancer advanced pancreatic cancercontinue falls normal starving organs tissues increase strongly tarceva approved oxygenit seen ofpatients second thirdline treatment ofnsclc chronic kidney renal disease condition countries worldwide april chugai affects million people worldwide filed application japan approval oftarceva anemia also seen cancer patients advanced recurrent nsclc filing undergoing chemotherapy potential long given priority review status authorities term effects anemia include cardiovascular dis market uptake oftarceva treatment ofpan ease renal patientswhile patients cancer creatic cancer also strongand product associated reduced survival dimin market leader us indicationin ished quality liferoche supports basic research january reexamining data support anemia funding ofthe independent ing roches supplementary marketing application roche foundation anemia research see pro eu authorities approved tarceva treat moting advances sciencep ment ofmetastatic pancreatic cancer business report pharmaceuticals despite sustained pricing pressure sales neo sales cellcept mycophenolate mofetil con recormon epoetin beta rose billion swiss tinued show solid growth driven francswith product retaining strong position particularly strong demand us thanks cancerrelated anemia market leadership proven longterm survival benefits low renal anemia regions soldas toxicity cellcept remains leading product market share gains oncology setting mycophenolic acid market cornerstone driven continued adoption conve ofimmunosuppressant therapies nient onceweekly prefilled syringe formulationin january eu authorities approved use virology onceweekly dosage form treat anemia patients solid tumoursin japan sales ofepogin combined sales valcyte valganciclovir epoetin beta declined due governmentman cymevene ganciclovir continued grow strongly dated price cuts introduction flatrate driven increasing recognition among reimbursement epoetin products used dialysis doctors need prevent treat cyto patients reduced overall size megalovirus infection transplant patientswhich anemia market combined sales neorecormon fatalsales also helped increased epogin declined slightly overall year use ofthe products treat cytomegalovirus infec tion hivaids patients mircerathe first continuous erythropoietin recep tor activatoris new antianemia agent differs influenzaor fluis highly contagious viral illness existing medicines functionally occurs mainly autumn winter structurallyin april roche filed first marketing months temperate climates yearround applications approval ofmircera treat anemia tropical areas particularly dangerous resulting chronic kidney diseasethe eu young childrenthe elderly people chronic us filings seek approval use product health problems every year million people patients dialysis fall ill flu europe japan us dialysis see major development activitiesp aloneinfluenza outbreaks occur every yearthough december fda accepted additional data extent severity vary widely pandemics submitted roche facilitate agencys review orglobal epidemicsoccur every years us marketing application extended affect halfthe worlds population review period three months trial patent lawsuit brought amgen us worldwide sales tamiflu oseltamivir contin expected begin september roche ued rise strongly driven mainly pandemic remains confident mircera infringe stockpilingas governments increased popula ofamgens erythropoietin patents tion coverage since countries placed orders pandemic stocks oftamifluwith transplantation purchasing enough cover oftheir populationsthrough collaborative network ofits number organ transplants performed facilities ofother companiesroche worldwide remains steady approximately access manufacturing capacity annually medical science extends life tamiflu exceeds government orders received expectancy patients transplanted organs dateresearch effective utilisation demand continues increase safe effective tamiflu hn virus continuing immunosuppressants control transplant rejec roche collaborations tion medicines combat infections associ independent experts world health organiza ated transplantation roche supports basic tion institutionsfollowing eu approval transplantation research funding tamiflu influenza prophylaxis children independent roche organ transplantation aged years medicine pre research foundation see promoting advances scribed treatment prophylaxis patients sciencep aged one year older business report pharmaceuticals balancing business responsibility planning pandemic influenza roches antiviral drug tamiflu may play key role managing next influenza pandemic tamiflu life cycle team working closely world health organization govern ments around world plan event using lessons learned role indeveloping strategy combat hivaids africa hn strain influenza currently circulating birds could lead human pandemic mutates intoa form transmitted easily person needed includes lowered uniform person governments began establishing price governments stockpiling drug pan national pandemic plans stockpiling medicines demic use deeper price reductions developing supplies tamiflu oseltamivir identified countries increase access worlds two critical antiviral demand soared populated countries granted sublicences major manufacturers india china pro roche boost production capacity meet vided technical knowhow south african manu surge demand without restricting availability facturer expedite production generic version drug treat prevent seasonal flu still oseltamivir africa causes thousands deaths year says pandemic taskforce leader david reddy second right addition roche donated million treatment teammembers october took courses send immediately epi additional suppliers expanded global manu centre pandemic outbreak one occur facturing network include multiple roche sites million regional stockpiles use contractors ten countries result poorer countries limited stocks drug annual production capacity increased million treatment courses end around contributions pandemic preparedness times capacity examples longstanding commitment working governments international agencies roche implemented balanced pricing patent stakeholders address major public health policy help ensure tamiflu available needs hepatitis b c viruses hbv hcv cause million new cases occur yearhepatitis c acute chronic liver diseasepotentially leading main reason liver transplantation liver failure cirrhosis liver cancer world wide million people thought chron despite overall decline market volume ically infected hbv highly infectious us competition combination treatment pathogen responsible estimated mil japan sales pegasys peginterferon alfaa lion deaths annuallymore million people treatment ofhepatitis b ccontinued around world infected hcvand grow product remains leading business report pharmaceuticals pegylated interferon treatment chronic hepati indication issued fda emea tis c sales copegus ribavirin continued use patients active ra decline overall due generic competition inadequate response unable tolerate us january chugai received approval antitnf therapylaunches useu else market copegus japan treatment commenced chronic hepatitis c combination pegasys actemra tocilizumab firstinclass humanised proven medicines diagnostic tests monoclonal antibody designed block inter roche contributes global effort combat leukin important protein involved hiv infection aidswe also continue help inflammation associated ra april improve standard hiv care worldwide chugai filed marketing application japan initiating supporting projects make use actemra treatment adult ra difference local level information systemic onset juvenile idiopathic arthritis initiatives roche help expand access supporting data include phase iii results showing hivaids treatment developing worldsee actemra monotherapy significantly improves playing active role p ofthis report visit symptoms ra slows progression httpwwwrochecomhomesustainabilityhtm joint damageroche plans file marketing appli cations actemra ra us eu roches hiv medicines achieved steady growth product currently approved japan throughout sales fuzeon enfuvirtide treatment castlemans disease rare works blocking entry ofhiv cells lymphatic condition see also major development immune system rose compared activitiesp combined sales invirase fortovase saquinavir increased million swiss major products franchises francsgrowth fuelled increasing uptake recently introduced invirase mg tablet osteoporosis causes gradual loss ofbone density offers patients greater convenience making bones brittle prone breakit affects millions people worldwide especially women rheumatoid arthritis menopause rheumatoid arthritis ra autoimmune dis bonvivaboniva ibandronic acid first order characterised joint inflammationbut oncemonthly oral bisphosphonate approved disease also affect lungseyes bone mar treatment postmenopausal osteoporosis roweven treatedit result progressive worldwide rollout gathered pace fullyear joint destruction loss mobility exact sales ofthe product continued rise stronglyin cause ofra unknownand yet cure us boniva accounts ofnew bis within two years developing raup phosphonate prescriptionsnew data published patients xray evidence joint damageand september show patients monthly boniva within ten years unable work perform tend continue treatment significantly longer everyday tasks ra one common taking weekly bisphosphonatesthus increas autoimmune disorders thought affect ing chances sustained treatment results million people worldwide current treat bonvivaboniva injection approved us ments include diseasemodifying antirheumatic europe january marchrespectivelyand drugs dmards biologic medications currently launched marketsgiven inhibit tumour necrosis factor tnf inflam every three months new formulation matory cytokine offers effective treatment women unable take tolerate oral bisphosphonates mabtherarituxan first therapy developed ra selectively targets b cells play global sales ofxenical orlistat mgfor weight key role disease first approvals lossgrew steadily despite launch business report pharmaceuticals advancing treatment rheumatoid arthritis traditional thinking mechanisms causing inflammation tis sue damage observed joints people rheumatoid arthritis ra challenged jonathan edwards professor medicine university college london immune cells called lymphocytes considered key factor driving ra however research carried edwards colleague geraldine cambridge suggested another type immune cell called b lymphocytes far important ra generally appreciated sented major new opportunity ra together led researchers focus potential role roche scientists began designing fullscale b cells edwards became convinced target clinical trial ing b cells could offer way preventing inflam mation deformity ra eight years clinical experience ritux imab ra clear product effective began looking medicine might capable welltolerated treatment option patients active achieving mabtherarituxan ritux disease also encouraging none imab selective bcell depleting monoclonal antibody patients treated prof edwards team shown effective treatment time shown sign becoming resistant ther typeof cancer called nonhodgkins lymphoma apy mabthera continues successfully control edwards cambridge decided put medicine disease number patients rituximab really test five patients longstanding severe godsend says edwards several patients rawho responded treatment whose ra severe unable get five rapidly showed major improvement num bed lunchtime get ber patients treated soon increased halfway also take walk day even gone back trial evident mabthera repre work new competitor number markets growth research development helped increasing awareness ofthe risks associated overweight obesityfollowing recent years roche group brought receipt approvable letter fda market effective new treatments many different april partner glaxosmithkline discus types canceras well medicines represent sions agency regarding application important advances treatment hepatitis sell orlistat mg nonprescription weightloss hiv osteoporosisroche aims expand aid ussubject final fda approvalgsk successes major areas auto expects launch product brand immune metabolic diseases disorders name alli first halfof central nervous system business report pharmaceuticals nine groups phase iii clinical trials met primary endpoints five major trials reported positive followup data product indication trial result actemra rheumatoid arthritis satori significantly improved disease scores acr acr compared methotrexate avastin xeloda metastatic colorectal cancer firstline treatment avastin significantly longer progressionfree survival compared chemotherapy alone xeloda least effective fluorouracil fu terms progressionfree survival combined oxaliplatin avastin renal cell carcinoma avoren significantly longer progressionfree survival compared interferon alone bonvivaboniva osteoporosis mobile followup sustained efficacy hip spine good tolerability years herceptin metastatic breast cancer combination significantly longer progressionfree survival anastrozole hormonal treatment tandem time progression compared hormonal treatment alone herceptin adjuvant breast cancer significantly longer overall survival hera month followup reduced risk death compared withchemotherapy alone herceptin adjuvant breast cancer significantly longer overall survival bcirg month followup reduced risk death compared treatment following completion adjuvant chemotherapy mabtherarituxan indolent nonhodgkins lymphoma significantly longer overall survival firstline treatment rcvp followup reduced risk death compared cvp alone mabtherarituxan rheumatoid arthritis significantly better inhibition structural reflex month followup damage joints compared methotrexate alone mircera renal anemia correction hemoglobin levels least effective epoetin dialysis patients amicus darbepoetin terms response rate mircera renal anemia correction hemoglobin levels least effective epoetin predialysis patients arctos darbepoetin terms response rate xeloda gastric stomach cancer ml least effective fu terms progressionfree survival withbetter response rates xeloda esophagogastric cancer real least effective fu terms overall survival significant overall survival advantage combined oxaliplatin xeloda metastatic colorectal cancer secondline treatment least effective fu terms progressionfree survival combined oxaliplatin business report pharmaceuticals foldout rd pipeline cid research projects major therapeutic areas roche pharmaceuticals currently projects january preclinical research across six therapeutic areas development projects eight therapeutic areasincluding phase transition pre oncology clinical clinical development central nervous system fifteen projects either terminated viral diseases reverted rd partnersof theseeight phase isix phase ii one phase iii respiratory diseases inflammatory autoimmune engaging partnerships bone diseases cardiovascular roche pharmaceuticals continued metabolic diseases strengthen rd portfolio entering flex ible licensing collaborative agreements complement groups inhouse activitiesdur ing year new agreements signedinclud roche groups many promising research ing nine product transactions research projects latestage development compounds technology collaborationsin addition three new testimony expertise codevelopment projects chugaiannounced research development specialists julyroche signed agreements second half commitment one goalcreating bring year plexxikon targeted cancer com ing market innovative clinically differentiated poundintermune protease inhibitors hepati medicines fifth consecutive year tis c actelion sp immunomodulator roche pharmaceuticals named sciences list autoimmune disorders ofthe top employers biotech pharma ceutical industries moving third place major development activities field ofover companiesgenentecha member ofthe roche groupwas ranked number one oncology roche partners continue explore roche continues refine rd selection crite benefits avastin tarceva xeloda herceptin ria maximise success projects reach mabtherarituxan additional important phase iii clinical testingthe costly time cancer indications also combination consuming part drug development process treatments comprehensive nine groups phase iii clinical trials clinical development programmes oncology successfully reached primary clinical end portfolio expanded promising points compounds progress clinical develop ment rd pipeline mode action avastin demon pharmaceuticals division filed new strating effectiveness wide range solid marketing applications gained regulatory tumoursroche genentech currently test approvalsat beginning divisions ing avastin eight distinct types cancer rd pipeline comprised clinical projects plans development another eight avastin including new molecular entities nmes studied phase iii trials adjuvant additional indications twentyfive nmes treatment colon cancer advanced currently phase phase ii five phase metastatic pancreaticprostate ovarian iii filed regulatory reviewin total cer also tested combination number latestage projects nmes addi tarceva nsclc combination tional indications increased ceptin drugs metastatic breast cancer business report jb eng pipeline uhr seite rd pipeline strengthened therapeutic area project id projectproduct generic name pharmacological class indication phase partner cardiovascular r dual ppar agonist type diabetes ii metabolic diseases r glucokinase activator type diabetes ii r type diabetes r type diabetes r glp glp analogue type diabetes ii ipsen bim r cetp inhibitor dyslipidemia ii japan tobacco jtt r anticoagulant hematology r mircera continous erythropoietin receptor activator renal anemia filed nephrology useu r cera continous erythropoietin receptor activator cancerrelated anemia ii inflammatory autoimmune r mabtherarituxan rituximab anticd monoclonal antibody rheumatoid arthritis dmard inadequate responders iii genentech biogen idec bone diseases r valcyte valganciclovir inhibitor cmv replication ulcerative colitis r multiple sclerosis r p kinase inhibitor rheumatoid arthritis ii r actemra tocilizumab humanised antiil receptor monoclonal antibody rheumatoid arthritis iii chugai filed jpn r actemra tocilizumab humanised antiil receptor monoclonal antibody systemic onset juvenile idiopathic arthritis iii chugai filed jpn r ocrelizumab humanised anticd monoclonal antibody rheumatoid arthritis iii genentech r ocrelizumab humanised anticd monoclonal antibody relapsed remitting multiple sclerosis ii genentech r pnp inhibitor autoimmune diseases transplantation biocryst r sp receptor agonist autoimmune diseases transplantation actelion r cellcept mycophenolate mofetil impdh inhibitor lupus nephritis iii aspreva r cellcept mycophenolate mofetil impdh inhibitor pemphigus vulgaris iii aspreva central r antiamyloid peptide antibody alzheimers disease morphosys nervous system r overactive bladder r depression r schizophrenia r anxiety r schizophrenia oncology r mabtherarituxan rituximab anticd monoclonal antibody chronic lymphocytic leukemia relapsed iii genentech biogen idec r mabtherarituxan rituximab anticd monoclonal antibody chronic lymphocytic leukemia st line iii r mabtherarituxan rituximab anticd monoclonal antibody indolent nonhodgkins lymphoma maintenance st line iii genentech biogen idec r omnitarg pertuzumab dimerisation inhibitor ovarian cancer ii genentech r omnitarg pertuzumab dimerisation inhibitor metastatic breast cancer ii genentech r tarceva erlotinib egfr inhibitor pancreatic cancer approved genentech osi pharmaceuticals us filed eu r tarceva erlotinib egfr inhibitor nsclc st line maintenance iii genentech osi pharmaceuticals r tarceva erlotinib egfr inhibitor adjuvant nsclc iii genentech osi pharmaceuticals r tarcevaavastin egfr inhibitor antivegf monoclonal antibody nsclc st line maintenance iii genentech osi pharmaceuticals r erlotinib bevacizumab r tarcevaavastin egfr inhibitor antivegf monoclonal antibody nsclc nd line iii genentech osi pharmaceuticals r erlotinib bevacizumab r epothilone solid tumours ii kosan biosciences kos r solid tumours genmab r solid tumours r epothilone solid tumours kosan biosciences kos r xeloda capecitabine fluoropyrimidine gastric cancer filed eu r xeloda capecitabine fluoropyrimidine adjuvant breast cancer iii r xeloda capecitabine fluoropyrimidine adjuvant colon cancer combo oxaliplatin iii r xeloda capecitabine fluoropyrimidine metastatic colorectal cancer st line combo iii r xeloda capecitabine fluoropyrimidine metastatic colorectal cancer nd line combo iii r xeloda capecitabine fluoropyrimidine adjuvant colon cancer combo avastin iii r avastin bevacizumab antivegf monoclonal antibody nsclc st line approved genentech us filed eu r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer st line combo paclitaxel filed genentech useu r avastin bevacizumab antivegf monoclonal antibody nsclc squamous ii genentech r avastin bevacizumab antivegf monoclonal antibody adjuvant colon cancer iii genentech r avastin bevacizumab antivegf monoclonal antibody metastatic colorectal cancer st line combo extension iii genentech r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer st line combo herceptin iii genentech r avastin bevacizumab antivegf monoclonal antibody pancreatic cancer iii genentech r avastin bevacizumab antivegf monoclonal antibody ovarian cancer st line iii genentech r avastin bevacizumab antivegf monoclonal antibody prostate cancer iii genentech r avastin bevacizumab antivegf monoclonal antibody nsclc previously treated cns metastases ii genentech r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer st line combo docetaxel iii genentech r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer st line combo nontaxanes iii genentech r avastin bevacizumab antivegf monoclonal antibody renal cell carcinoma iii genentech r solid tumours r herceptin trastuzumab antiher monoclonal antibody metastatic breast cancer filed eu genentech combination hormonal therapy r herceptin trastuzumab antiher monoclonal antibody gastric cancer iii r braf kinase inhibitor malignant melanoma plexxikon respiratory diseases r nuclear receptor agonist emphysema ii viral r valcyte valganciclovir inhibitor cmv replication cytomegalovirus extension treatment iii infectious diseases r antibiotic bacterial infections ii sankyo cs r polymerase inhibitor hepatitis c ii r hepatitis c maxygen r polymerase inhibitor hepatitis c pharmasset r protease inhibitor hepatitis c intermune optin opportunities altu growth hormone deficiency ii genentech anticd anticd monoclonal antibody nonhodgkin 's lymphoma ii genentech anticd anticd monoclonal antibody chronic lymphocytic leukemia multiple myeloma genentech apoltrail cancer genentech parp inhibitor malignant melanoma genentech r calcineurin inhibitor renal transplant ii isotechnika isa r alzheimers disease memory pharmaceuticals r ef modulator solid tumours ii arqule arq r avastin bevacizumab antivegf monoclonal antibody glioblastoma multiforme ii genentech r avastin bevacizumab antivegf monoclonal antibody adjuvant breast cancer hernegative ii genentech r avastin bevacizumab antivegf monoclonal antibody ovarian cancer nd line ii genentech r avastin bevacizumab antivegf monoclonal antibody gastrointestinal stromal tumour iii genentech r avastin bevacizumab antivegf monoclonal antibody adjuvant rectal cancer iii genentech r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer nd line iii genentech vegf topical vegf diabetic foot ulcer ii genentech tp colorectal cancer chugai trastuzumabdm metastatic breast cancer genentech r mabtherarituxan rituximab anticd monoclonal antibody primary progressive multiple sclerosis iii genentech r mabtherarituxan rituximab anticd monoclonal antibody lupus nephritis iii genentech r mabtherarituxan rituximab anticd monoclonal antibody ancaassociated vasculitis iii genentech r mabtherarituxan rituximab anticd monoclonal antibody systemic lupus erythematosus iii genentech participation avs antevas nicaraven hydroxyl radical scavenger subarachnoid hemorrhage filed jpn chugai ed activated vitamin derivative osteoporosis iii epoch epogin epoetin beta chemotherapyinduced anemia filed jpn gm mitemcinal fumarate motilin agonist gastroparesis irritable bowel syndrome ii sg sigmart nicorandil acute heart failure filed jpn val valine posthepatectomy ii participation lucentis ranibizumab antibody fragment vegf diabetic macular edema ii genentech xolair omalizumab antiige antibody pediatric asthma iii novartis tanox hae asthma ii beginning pharmaceuticals divisions rd pipeline comprised projects including phase initial studies healthy volunteers possibly patients new molecular entities nmes additional indications twentyfive nmes currently phase phase ii efficacy tolerability dosefinding studies patients eighteen phase ii five phase iii filed regulatory review phase iii largescale studies patients statistical confirmation ofsafety efficacy bluetype signifies first indication blacktype additional indications therapeutic protein current january small moleculepharmaceuticals results phase iii avastin lung trial hematology nephrology anemia bowhich exploring combination results ofsix major phase iii trials ofmircera avastin chemotherapy firstline treat renal anemia involving patients ment ofadvanced nsclcare expected first chronic kidney disease presented halfof major medical conferences data showthat dialysis patients switched directly phase ii study investigating combined herceptin successfully maintenance therapy avastin without chemotherapy first oncemonthly mircera medicines line treatment herpositive metastatic breast requiring administration three times week cancer showed patients first time switch achieved complete partial response tumour shrinkage addition two studies anemia correction recruitment started phase iii trial previously untreated patients chronic averel investigate adding avastin kidney disease demonstrated mircera ceptin plus docetaxel firstline treatment given patients twice monthly metastatic breast cancerroche genentech also outset another first clinical development plan investigate combined avastin herceptin mircera chemotherapyinduced anemia adjuvant herpositive breast cancer set cancer patients currently phase ii pro ting ceeding planned roche partners currently evaluating rheumatology autoimmune diseases mabtherarituxan phase iii trial mainte new clinical results published use nance therapy following firstline treatment mabtherarituxan patients rheumatoid product indolent nonhodgkins lym arthritis ra responded therapy phomamabtherarituxan also evaluated one tnf inhibitors included two phase iii programmes firstline treat firstradiographic evidence mabtherarituxan ment therapy relapses chronic lym significantly inhibits joint destruction data phocytic leukemia showing continued benefit additional treat ment courses drug development heraa major phase iii trial herceptin product broader group ra patients given women earlystage breast cancer mild moderate disease responded months continues data adequately treatment diseasemodifying announced study maturesherceptin also antirheumatic drugs dmards track evaluated phase iii trials treatment four phase iii trials progress ofherpositive stomach cancer actemra developed treatment ra xeloda currently developed adjuvant one extensive phase iii programmes breast cancer setting recruitment patients roche ever undertaken five clinical trials large phase iii study ofthe product combined patients currently ongoing docetaxel completed january countries patient enrolment completed december omnitarg pertuzumab dimerisation inhibitor developed treatment ocrelizumab anticd humanised mono ovarian breast cancer results recent clonal antibody developed roche phase ii study ofomnitarg plus gemcitabine versus genentech moderate severe rheumatoid gemcitabine alone advanced platinumresis arthritislike mabtherarituxanocrelizumab also tant ovarian cancer encouragingresults targets b cellsas fully humanised antibodyit phase ii study drug platinumsensitive potential even better toleratedpromising ovarian cancer expected results phase iii data presented american studies form basis decision college ofrheumatology conference november progression phase iii development showing ocrelizumab well tolerated business report pharmaceuticals actemra partnering action actemra tocilizumab humanised mono clonal antibody designed block inflamma tioncausing protein called interleukin il first drug class rheumatoid arthritis ra first antibodybased drug originate japan roche chugais first codevelopment project actemra selectively targets il receptor blocking activity il protein plays major role inflammation characterises ra clinical trial data indicate actemra dramatically reduce painful disabling symptoms joint damage ra years rd experience drug con since lifecycle team scientific medical tributing global development marketing expertise business specialists roche chugai managing actemra project includes collaboration chugai roche excellent five phase iii clinical trials centres countries chugai successfully markets major roche medicines team headed roche life cycle leader japan currently seeking japanese regulatory maclean hiroyuki ohta senior vice president approval others including avastin research head mra unit chugai pictured companies complementary expertise inter right second right team members ests small molecules therapeutic antibodies share insights technologies actemra story story partnering diversity members lifecycle team bring broad range next codevelopment projects already lined strengths perspectives common goal july companies signed agreements covering developing commercialising actemra worldwide three new chugai compounds two cancer one roche people able learn chugais ten diabetes clinically active tested doses extensive metabolic disorders phase iii clinical development programme type adult onset diabetes recognised planned start early global epidemic estimates mil lion people worldwide disease additionroche developing ran oral p roche currently investigating dif map kinase inhibitor moderate severe ra ferent biological targets screening drug candi inhibition enzyme p map kinase reduces dates production key mediators inflammation currently phase ii clinical testing r blood glucose control depends largely secre potential offer increased safety efficacy tion insulin beta cells pancreas easier administration compared currently response fluctuations glucose levelshowever available dmards also related glucose production business report pharmaceuticals building future already world leader biotech manufacturing capacity roche group continues invest inthe future meet rising demand ther apeutic antibody products roche building stateoftheart biotech facilities produce avastin herceptin basel switzerland penzberg germany together two projects represent investment million swiss francs facilities built tight schedules ensure fully operational manufacturing groups markets project teams sites share strong sense urgency also employing fasttrack projects within budget ahead schedule approach means design engineering construction buildings completed phases take place concurrently resulting significant two years equipment installed time savings commenting advantages daniel next two years final commissioning qualifi riekert pictured standing project manager cation take place well final regulatory inspec basel says fasttrack approach makes possible tions speed two facilities complete complex building projects faster ever become operational four years total remark weve accumulated lot experience able says penzberg project manager claus herrmann area share engineering colleagues seated right shows committed com genentech chugai knowhow benefits pany ensuring biotech medicines avail entire roche group able patients tightly controlled liver glucokinase closely mimics action natural human enzyme plays key role organs hormone glp offers potential weekly targeting pathways r roches first longer administration intervalsunlike glp inclass oral glucokinase activator designed analogues r far provoked anti provide better control type diabetes body responses ofthe people given drug current standard therapy r currently phase iib study currently preparedwith phase ii clinical trials roche also developing first administration planned early compounds act glucokinase components glucose metabolism potential dyslipidemia treatments type diabetes lack ofhighdensity lipoprotein cholesterol hdl c good cholesterol associated july roche announced exercising increased risk cardiovascular disease r option licensedevelop market r bim licensed japan tobaccois cholesteryl ester longacting glucagonlike peptide transfer protein cetp inhibitor unique glp analogue developed ipsen type mechanism ofaction designed raise levels diabetes r similar structure ofhdlcphase ii studies nearing completion business report pharmaceuticals data indicate compound good roche pharmaceuticals currently investing safety profile desired effects hdlc around billion swiss francs manufacturing blood lipids fatsthe results stud infrastructure projects including major biotech ies form basis decision facilities produce active ingredients entry phase iii testingunlike development avastin herceptin basel switzerland compound class recently penzberg germany new formulation filling discontinued another company r packaging logistics facilities injectable associated adverse cardiovascular infusable medicines kaiseraugst switzerland changes increase blood pressure mannheim germanyand facility toluca given patients monotherapy combina mexico formulation highly potent tion statinsnor r affect cardiovascu medicines xeloda lar parameters animal models virology chronic infection hcv genotype one difficult types ofhepatitis c treatthis viral subtype found largest subgroup patients hepatitis conly ofpatients hcv genotype respond current treat mentsand many experience severe side effectsto meet need new treatment options roche several novel antihcv agents clinical devel opment r currently phase ii potent inhibitor hcv polymerase enzyme essential replication virus addition two compounds partnerships pharm asset maxygen entered phase clinical testing central nervous system diseases diseases central nervous system represent greatest unmet medical needs world wide one largest segments global pharmaceuticals marketroche currently eight projects early clinical development area including promising phase compounds alzheimers diseaseschizophrenia depression manufacturing infrastructure last yearsroche systemati cally developing manufacturing infrastructure line ongoing changes groups prod uct mix meet current expected demand new biologic medicines addition ensure manufacturing operations remain effi cientcosteffective environmentally compati ble continually incorporating improved technology updating processes line best practices business report diagnostics division brief sales millions chf operating profit exceptional items millions chf published annual report number employees key figures change change millions chf chf local currencies sales sales diabetes care centralized diagnostics molecular diagnostics near patient testing applied science ebitda operating profit research development exceptional items diagnostics executive committee january severin schwan ceo division roche diagnostics perolof attinger platforms support silvia ayyoubi human resources manfred baier applied science christian hebich finance services daniel oday molecular diagnostics tiffany olson north america volker pfahlert professional diagnostics burkhard g piper diabetes care jrgen schwiezer emea europe middle east africa latin america robert yates business development business report diagnostics division sales region roche diagnostics world leader invitro diagnostics products used test human body europemiddle east fluids tissues obtain information africa diagnosis prevention treatment disease japan andit also supplier innovative solutions asiapacific medical biotechnology researchthe divisions others large growing product portfolio ranges iberia home blood glucose monitoring products latin america people diabetes pointofcare testing north america devices use doctorsoffices highthrough put laboratory systems hospitals stateof italics growth rate theart instruments genetic research october food drug administration division rd manufacturing facilities fda lifted import alert barring us sale austria germany switzerland united accuchek insulin pumps disetronic medical states augmented extensive network systemswith new accuchek spirit pump alliances partnerships giving division broad available worlds largest infusion systems access important new technologies using market roche expects strengthen capabilities help make todays healthcare market leadership diabetes care bettersafer costeffective provide scientists tools needed discover tomor divisional operating profit exceptional rows medical advances items declined billion swiss francs resulting margin decline percentage pointsthis primarily due increased invest results ments launch activitiesimpairment charges intangible assets lower royalty income roche diagnostics remained global leader licencesthe impairment charges mainly relate increasingly competitive market intangible assets recorded following disetronic market share divisional sales increased acquisition decline royalty income year local currencies swiss followed worldwide expiry ofthe foundational francs us dollarsfuelled new product patents polymerase chain reaction pcr tech launches slightly market nology many countries outside usebitda growth rate centralized diagnostics near patient testing applied science units unless otherwise stated growth rates local cur main contributors growth roche diabetes rencies cares sales grew earnings exceptional items financial income financing costs tax depreciation amortisation including impairment business report diagnostics totalled billion francsor salescom united states customers access pared well complete roche portfolio insulin delivery industry average products since fda lifted import alert accuchek insulin pumps october customer response accuchek spirit business areas pumpwhich available coun trieswas positive first three months diabetes care us market roche diabetes cares insulin delivery business posted doubledigit growth roche diabetes care supplies broad range blood glucose meters insulin delivery systems centralized diagnostics better diabetes managementmonitoring systems integrated lancetstest strips software laboratory workloads increasing storing analysing data increasingly growing demand tests detect diseases early important part roches diabetes care portfolio targeted therapiesat time improve glucose control many hospitalbased commercial laboratories usersin addition offering greater convenience pressure contain cut costs roche activities aimed integrating glucose monitoring centralized diagnostics supplies instruments data management insulin delivery testsdata management software services ongoing may one day result systems enablelaboratories cope challenges closely mimic way healthy pancreas regu simplifying workflows enhancing productivity lates blood glucose levels efficiency roche diabetes care remained global market roche centralized diagnostics posted leader following growth first abovemarket sales growth remained halfyear sales rose third quarter industry leader market share fourthfullyear sales rollout ofthe mediumthroughput cobas previous year analyser series european launch cobas c analyser customers small testing new accuchek product portfolio makes volumes marked important steps business even easier people diabetes manage strategy centred making clinical chemistry condition besides accuchek spirit insulin immunochemistry testing simpler effi pumpit includes accuchek aviva accu cientan application us marketing approval chek go blood glucose monitoring systems cobas c analyser submitted fda accuchek compact plus allinone system late cobas analyser series isafully integrating aglucose meter automatic test automated integrated system capable handling strip dispenser lancing devicealso new routine tests performed accuchek multiclix lancing devicewhich features dailyby mediumvolume laboratorythanks unique preloaded lancet drum safer flexiblemodular designit configured exactly convenient comfortable blood sampling customers individual needs new modules market uptake products strong added time needs grow spurring additional sales growth helping set declining sales oftheaccuchek advantage sys immunoassay sales continued grow significantly temone roche diabetes cares successful faster market advancing products nearly decade rollout new thanks products like elecsys probnp monitoring systems completed mid elecsys troponin assays cardiac disorders launch oftheaccuchek compact plus sales ntprobnp marker grew helped north america accuchek aviva japanthe additional us approval elecsys probnp entire new family accuchek products assay use assessing risk cardiac events available worldwide patients stable coronary artery disease business report diagnostics consolidation flexibility cobas tergooi hospitals neighbouring towns hilversum blaricum netherlands recently merged together beds eric vermeer pictured frits fernhout two visionary young doctors hospitals charge europes first reference laboratory equipped instruments roches cobas analyser series ambition next several years make one netherlands ten best reference labs june laboratory became one first install new analysers handling grows next years hope one important reason choosing cobas adapting expanding system cope analyser series consolidation allows us per higher workload wont problem form clinical chemistry immunochemistry testing add another cobas e cobas c single platform says dr vermeer space module simple savings significant used two relatively large clinical chemistry analysers plus third improved workflow efficient use staff system immunoassays today two new work lab shorter turnaround times cobas instruments instead capable serving lower costs advantages dr vermeer backup intend use extra space dr fernhout experienced firsthand since expand range tests laboratory offers switch cobas analyser series staff like standardised userfriendly interface another selling point us systems flexibility software switch master two adds dr fernhout volume test orders different operator interfaces days molecular diagnostics roche molecular diagnostics maintained lead ing market share sales advanced roche molecular diagnostics develops com yearvirology largest segment mercialises innovative highly sensitive systems sales grew line virology tests reliably detect bacteria viruses market pathogens patient samples donated bloodtissues organsthese products use tech steppedup sales efforts combined cobas nologies directly detect genetic material ampliprepcobas taqman platform menu dna rna ofinfecting pathogens hiv viral load tests hiv hepatitis b c hepatitis viruses therefore provide faster virus hbv hcv drove product sales results tests based bodys immune helped roche molecular diagnostics maintain response infection business area also market share europe offering fully auto working additional genebased tests facilitate mated sample preparation analysis cobas differential diagnosis treatment selection ampliprepcobas taqman enhances laboratory number ofother diseases productivity test result integrityfda review business report diagnostics hiv viral load test platform already monitoring coaguchek xs plus healthcare well advanced roche preparing submit professionalscommenced european rollout marketing application hcv test january october respectively coaguchek xs fda early monitoring viral load received fda approval third quarter amount virus patients blood impor full us launch planned first quarter tant way ofassessing disease progression treat systems provide patients taking oral ment response anticoagulants health professionals accu rateonthespot results single drop ofblood june roche began rolling new fully successful launch strengthened roches automated cobas modular blood screening global leadership coagulation monitoring system cobas taqscreen mpx multiplex test across europe cobas taqscreen mpx test roche near patient testing also clear leader simultaneously detects hivhcv hbv hospitalbased blood glucose monitoring donated blood received ce mark conformit accuchek inform meter accuchek advan europenne certification march prod tage accuchek sensor test strips core ucts available european countries products driving roches growing market share us filings multiplex test separate segment west nile virus test cobas system planned applied science year additional large us laboratories life sciences encompass disciplines ranging signed offer amplichip cyp test biology genetics proteomics medical microarraybased test detects genetic varia research major disease areas cancer tions affect way patients respond virology roche applied science supplies broad treatment many widely prescribed drugs growing array instruments highly spe cific test reagents test kits research applica roche preparing submit filings fda tions diverse market first half tests detect geno type low intermediate highrisk strains roche applied sciences sales grew human papillomavirus hpvpersistent infection nearly twice market growth rate growth certain hpv genotypes known risk factor driven primarily lightcycler cervical cancer instrument genome sequencer system lightcycler highly versatile highthrough near patient testing put gene expression mutation analysis plat form based polymerase chain reaction roche near patient testing supplies products pcr technology pioneered rochethe inno use outside central laboratory example vative genome sequencer systemfirst launched physiciansoffices patientsbedsidesportable late marks roches successful entry diagnostic monitoring devices rapid simple attractive dna sequencing research market toperform tests advanced software support sequence long dna fragments entire clinical decisionmaking point ofcare genomes times faster conventional com core product groups mercially available instruments business area reinforced market leadership roche applied science also supplier indus overall sales rose yearhelped trial reagents substrates account continued trend towards decentralised major part sales revenues products testing important contributors growth roche near patient testings newest coagulation monitoring systemscoaguchek xs patient self business report diagnostics major product launches business area product diabetes care new accuchek go meter offering improved feature set design accuchek smart pix small easytouse device reader transfers data accuchek pump blood glucose meter users pc centralized diagnostics cobas analyser series integrated clinical chemistry cobas c module immunoassay cobas e module platform midvolume laboratories designed easy onsite expandability cobas c standalone clinical chemistry electrolyte analyser extrasmallworkload laboratories cobas solution laboratory information system supports steps laboratory testing order entry result reporting features connectivity sample management quality control validation capabilities molecular diagnostics cobas taqscreen mpx multiplex test multiplex test detection hiv groups hiv hepatitis b c cobas system used screen whole blood plasma organs tissues living donors lightcycler septifast test ce rapidly reliably detects identifies pathogens responsible bloodstream infections near patient testing coaguchek xs plus handheld coagulation monitoring system professional use coaguchek xs handheld coagulation monitoring system selftesting applied science lightcycler instrument new well format software modules extending systems broad range applications research development regimens business area exploring projects ranging safer convenient lancing roche diagnostics invested million devices insulin guidance software decision swiss francsor salesin research devel support programs designed help physicians opment molecular diagnostics immuno patients make better treatment decisionsa second chemistry diabetes care businesses accounted generation continuous glucose monitoring system largest shares ofexpenditure among projects currently develop ment diabetes care centralized diagnostics roche diabetes care pursuing continuous improvements integrated blood glucose moni following rollout cobas toring integrated systems reduce number analyser series roche centralized diagnostics different devices steps required track blood preparing launch second cobas modular glucose levels making easier people platform new platformwhich diabetes adhere diabetes management marketed cobas analyser seriesis geared business report diagnostics key product launches scheduled business area product diabetes care accuchek performa blood glucose monitoring system gives test results five seconds performs extensive quality checks includes advanced data management features accuchek easytouse customisable pcbased data management software designed wide range uses downloading data performing detailed analyses people diabetes healthcare professionals new accuchek compact plus blood glucose monitoring system improved userfriendly design ergonomic user interface professional diagnostics cobas e standalone immunochemistry analyser small mediumworkload laboratories successor elecsys mpa connectivity cobas analyser series connectivity hardware software cobas modular preanalytics modules offers laboratories total automation sample preparation result additional configurations cobas analyser series combining cobas c cobas e modules cobas cobas cobas cobas new configurations designed suit even wider range laboratory workloads cobas c system standalone clinical chemistry analyser small mediumworkload laboratories mylabview portal online benchmarking results obtained serum work area analysers cobas solution central lab data management system wammiddleware instrument interface consolidation providing resultrelated reagent test information cobas solution work area manager hospital point care product updates released periodically throughout cobas h portable system bedside fixedlocation cardiac testing test menu roche cardiac assays cobas h handheld meter measuring cholesterol triglycerides lactate blood designed professional selftesting environments molecular diagnostics cobas taqman hbv test automated realtime pcr amplification quantitation hepatitis b virus us cobas taqscreen wnv test cobas system automated realtime pcr detection west nile virus donated blood plasma us cobas ampliprepcobas taqman hiv hbv hcv tests automated realtime pcr amplification quantitation hiv hepatitis b c virus hiv us hiv hbv hcv japan applied science broad rollout genome sequencer flx nextgeneration dna sequencing system even faster costefficient roches ultrafast genome sequencer includes roche centralized diagnostics roche near patient testing business report diagnostics needs oflowworkload laboratoriesit com ofserious psychiatric diseasesalso roche prises cobas e immunoassay system explore use amplichip cyp test scheduled launch early cobas identify variations cypd gene c clinical chemistry system due follow inhibit metabolism conversion breast thesecond halfofthe yearthe cobas e system cancer drug tamoxifen body active provides results critical assays little form women cypd variants make nineminutes poor metabolisers tamoxifen shown receive less therapeutic benefit proteomics research roche identified several drug novel biomarker candidates colorectallung breast cancer rheumatoid arthritis near patient testing molecular diagnostics roche near patient testing continue renew broad product portfolio launches one ofroche molecular diagnosticstop priorities new instruments testing cardiovascular param develop secondgeneration multiplex blood eters hospital going forward overall screening assay indicate whether focus developing instruments offer unit blood positive viral contamination greater ease ofuse test consolidationin partic also identify virus present hiv ular efforts aimed addressing needs groups ohivhbv hcvthis automation intensive care units eliminate need separate viral target resolu settings frequent testing required tiontestingwhich required firstgeneration multiplex assays make screening effi applied science cient development activities aimed improving oncology first phase rochesponsored throughput sample handling international research study shown successful lightcycler instrument genome microarraybased analysis leukemias distin sequencer system ongoing nextgenera guishes different subtypes accurately conven tion sequencing system genome sequencer flx tional methods subject less interlabora become available first halfofroche tory variationidentifying leukemia subtype applied science also plans add new research patient critical selecting best avail reagents products automated cell analysis able treatmentdata study used toits portfolio determine gene sequences include amplichip leukemia microarray develop ment could potentially provide physicians single standardised test diagnosing leukemia subtypesin additionroche develop ing amplichip p test identify mutations p gene disable normal cell function allow cancer cells proliferate mutations p found virtually tumour types test may one day help assessing prognosis patients cancer selecting therapies best suited individual needs roche receive initial data large scale study correlating variations two cyp genes cypd cypc clinical comes treatment costs inpatient treatment business report little brother caught flu still got go holidays business report tamiflu stopping flu tracks tuesday late februarythe weather reportsaid snow conditions idealand weeks accommodation already bookedkristina anddiana three days school whole family due leave annual skiing tripunfortunatelyit brother niklas suddenly became illrapidly devel oping fever headacheand instead hisusual happyactive selfthe sixyearold showed interest anything much rest alerted recent news stories influenza outbreaks part germanythe childrens mother immediately took niklas familys pediatricianhe promptly diagnosed flu andpre scribed treatment tamiflu oseltamivir inadditionsince family members bynow probably also exposed flu virus doctor advised take tamiflu prophy laxisthe whole family started taking medicine dayafter mother showed girls niklas measured correct doses oftamiflu suspension themselvesusing dispenser provided everyones reliefniklas made rapid recovery prophylaxis also successful one else family came fluthe following saturdaythe family able take mountains planned prevention influenza disrupt holiday plans illness devastating consequences year seasonal influenza affects million people worldwide deaths attributed disease us alone children elderly risk along people whose health already compromised conditions treating initial case tamiflu giving tamiflu prophylaxis family members proving effective preventing transmission influenza within households business report corporate governance remuneration report corporate governance roche meets relevant corporate governance mauro elected new member roches requirements particular complies highest governing body also term four applicable laws swiss stock exchange yearsrolfhnggiwho served vicechair swx swiss exchange directives including man ofthe board ofdirectors since declined commentaries thereto swiss code best stand reelection agm practice corporate governance promulgated swiss business federation economiesuisse organising meeting immediately following companys internal governance frameworkpar agmthe board directors adopted changes ticularly articles incorporation bylaws committee structure committee member embodies principles needed ensure ships shown table inparticu companys businesses managed super larthe audit corporate governance commit vised manner consistent good corporate tee reconstituted audit committeeand governance including necessary checks responsibility corporate governance sustain balances ability reporting legal compliance safety health environmental protection printed annual report contains selected links previously part audit corporate roche website wwwrochecomreaders governance committees remitwas transferred thus provided snapshot newly established corporate governance company reporting date also directed sustainability committeechaired andreas oeri sources consult time finance investment committee dis uptodate information corporate govern solved remit transferred new audit ance rochewhereas annual report covers committeechaired deanne julius single financial year ending december website contains information ofa permanent next annual general meeting roche nature well latest roche news amend shareholders march board ofdirec ments companys articles incorporation tors propose pius baschera wolfgang bylaws changes curricula vitae ofthe ruttenstorfer elected additional members members ofthe board ofdirectors corpo board rate executive committee published timely fashion websitewhere accessed pius baschera swiss citizen born anyone looking information chairman board hilti corporation since start ofafter completing degrees mechanical engineering management studies board directors swiss federal institute oftechnologyzurich pius baschera joined hilti held num th annual general meeting agm ber positions united states europe roche holding ltdon february deanne juliuspeter brabeckletmathe horst teltschik elected additional fouryear terms board directorsin additionbeatrice weder di httpwwwrochecomhomecompanycomgovhtm business report corporate governance board directors january leftjohn bell beatrice weder di mauro peter brabeckletmathe brunogehrig andrhoffmann franz b humer lodewijk jr de vink deanne julius walter frey andreasoeri horst teltschik name year birth term ends first elected board directors dr franz b humer f chairman prof bruno gehrig c e vicechairman independent lead director andr hoffmann c e vicechairman prof john irving bell c e peter brabeckletmathe e lodewijk jr de vink c e walter frey b e dr deanne julius b e dr andreas oeri e prof horst teltschik b e prof beatrice weder di mauro b e secretary board directors dr gottlieb keller honorary chairman board directors dr fritz gerber corporate governance sustainability committee presidiumnomination committee b audit committee e nonexecutive director c remuneration committee f executive director committee chairperson january business report corporate governance appointed cfo information relating corporate became chairman ofthe executive boarda position governance stepped became chairman ofthe board january pius baschera group structure shareholders honorary professor swiss federal institute roches operating businesses organised technologyzurich two divisionspharmaceuticals diagnostics pharmaceuticals division comprises wolfgang ruttenstorferan austrian citizen born three business segments roche pharmaceuticals graduate vienna university eco genentech chugai nomics business administrationsince diagnostics division consists follow ceo chairman ofthe executive board ing five business areasapplied sciencediabetes omv aktiengesellschaftin addition heading care centralized diagnostics molecular diag companys natural gas chemicals busi nostics near patient testingbusiness activi nesses wolfgang ruttenstorfer joined omv ties carried group subsidiaries appointed executive board associated companies significant subsid austrias deputy iaries associated companies listed minister finance returning omv finance report note roche group wolfgang ruttenstorfer recognised expert consolidated financial statements subsidiaries emerging markets eastern europe associated companiespages middle east major shareholders listed finance report notes roche group consolidated financial statements equity corporate executive committee attributable roche shareholdersand related parties pages notes severin schwan joined corporate executive financial statements roche holding ltd committee new ceo division roche diag nostics january heino von prondzynski andr hoffmann vicechairman board former ceo division roche diagnosticsresigned directors andreas oeri chairman roche end theboards corporate governance sustain ability committee serve respective effect january burkhard g capacities board committees pipereduard holdenerpeter hugrolf schlpfer representatives shareholder group osamu nagayama appointed members pooled voting rights receive remunera roches enlarged corporate executive committee tion set forth remuneration report relationships exist effective january pascal soriot head shareholders pooled voting rights pharma strategic marketing became head crossshareholdings commercial operations pharmaceuticals division joined enlarged corporate exe capital structure cutive committee information roches capital structure pro vided finance reportnotes finan cial statements ofroche holding ltd additional details contained articles incorporation ofroche holding ltd changes equity detailed finance report notes financial statements roche holding ltd httpwwwrochecomhomecompany comgovcomgovartihtm business report corporate governance corporate executive committee december leftjonathan kc knowles pierre jaccoud severinschwan burkhard g piper william burns eduard holdener franz b humer peter hug erichhunziker rolfschlpfer gottliebakeller osamu nagayama name year birth position corporate executive committee dr franz b humer chairman ceo roche group dr erich hunziker chief financial officer deputy head corporate executive committee william burns ceo division roche pharmaceuticals dr severin schwan ceo division roche diagnostics prof jonathan kc knowles head global research dr gottlieb keller head corporate services human resources enlarged corporate dr eduard holdener head global pharma development executive committee dr peter hug head pharma partnering burkhard g piper head business area roche diabetes care pascal soriot head commercial operations pharmaceuticals division rolf schlpfer head corporate communications osamu nagayama president ceo chugai secretary pierre jaccoud head chairmans office corporate executive committee statutory auditors kpmg klynveld peat marwick goerdeler sa since roche holding ltd principal auditor john morris since group auditors compliance officer dr andreas greuter business report corporate governance company share capital see articles incorporation swiss francsdivided fully paid roche holding ltd minutes th bearer shares nominal value swiss annual general meeting roche holding ltd franc eachthere restrictions exer held february cise voting rights shares upon chairman board directors franz b depositshares voted without restric humer continues director also tions serving executive capacity roche authorised conditional capital majority seats board directors addition nonvoting equity secur held independent directors ities nes issued bearer form none nonexecutive members form part share capital board ofdirectors member ofroches confer voting rights nes confers corporate executive committee served rights one share participate avail executive capacity group subsidiary able earnings liquidation proceeds three financial years preceding following repayment ofthe share capitalroches current reporting period nes rights pertaining thereto including internal organisation ofthe board ofdirec provisions protecting interests nes tors division authority responsi holders described articles bilities board managementthe incorporation ofroche holding ltd remits ofthe board committees informa information debt instruments tion control mechanisms available issued outstanding bonds pro board dealings corporate manage vided finance report note ment governed bylaws roche group consolidated financial statements board directors roche holding ltd debt organised ensure groups busi additional information employee stock nesses conducted responsibly options provided finance reportnote focus longterm value creation end roche group consolidated financial roche board delegated certain responsi statements employee stock options bilities several committees composi equity compensation benefits tion chairpersons january roche issued options apart employee described stock options stocksettled stock appreciation committees except presidium rights ssars options issued connec chaired independent directors tion debt instruments articles ofthe bylaws neither options awarded employees board directors independent lead debt instruments issued director may discretion effect roches share capital request ofany memberconvene board meeting without chairman presentthe roche board board directors corporate executive meets year assess chairmans per committee formancethis meetingwhich attended information member board chairman chaired independent directors including years lead director elected years terms end member corporate executive httpwwwrochecomhomecompanycomgovhtm committee listed pages httpwwwrochecomhomecompany curricula vitae information includ comgovcomgovartihtm httpwwwrochecomhomecompany ing information board memberships comgovcomgovgvhtm available internet httpwwwrochecomhomecompany annual general meeting elects members comgovcomgovbylawshtm board directors staggered elections httpwwwrochecomhomecompany nominee voted separately comgovcomgovcomhtm business report corporate governance board ofdirectors regularly conducts self chairman secretary board assessment ofits performance directors always present board meetings board directors established system except board discussing per ofcontrols overseen audit com formance remunerationthe members mittee corporate governance corporate executive committee sustainability committee consists ofthe fol invited attend report person lowing elements agenda items concerning themwhen reports financial operating risks situation warrants members enlarged internal audits corporate executive committee may also compliance officer invited attend board committees invite safety health environmental protection chairman ofthe board corporate department executive committee members deliver reports corporate sustainability committee committee meetings may elect commis scientific ethics advisory group seag sion independent expert reports call issues relating genetics genetic engi services consultants risk management neering established system subject continuous review year several blackout periods imposed review findings presented audit senior employees prohibited committee full boardinternal audit regu trading company stock following larly briefs audit committee reference blackout periods effect ongoing audit reports members internal january february audit attend audit committee meetings april april external auditorsfor information exter july july nal auditorssee october october management contracts fall blackout periods changed chair within meaning ofsubsection ofthe swx man board directors circumstances directive information relating corporate warrant governance board directors met four meetingseach hours lengthonce remuneration shareholdings loans fullday meetingand threeday details regarding remuneration sharehold official trip included additional board ings loans set forth remuneration directors meeting board committees report pages met follows presidium ofthe board ofdirectors participatory rights shareholders nomination committeefive meetings participatory rights shareholders approxhours defined roches articles incorporation audit committeethree meetings roche shares issued bearer approxto hours norestrictions admission annual general corporate governance sustainability meetingswith exception shares must committeetwo meetings approx hours deposited within specified period date meeting admittance card must remuneration committeetwo meetings issued shareholders nameas provided approx hours articles incorporation audit corporate governance committee shareholder elect represented discontinuedone meeting approx hours another shareholder annual general meet finance investment committee discon ing articles incorporation contain tinuedone meeting approx hours restrictions exercise voting rightsand figures indicate actual length meetings include directors extensive premeeting prepara httpwwwrochecomhomecompany tions postmeeting followup activities comgovcomgovartihtm business report corporate governance quorum requirements stipu lated compliance swiss code millions chf ofobligations auditing services articles incorporation auditrelated services shareholders representing shares nominal tax consultancy services value ofat least million swiss francs request total placement items agenda annual general meetingthis must done group auditors statutory auditors later days date ofthe meeting elected year annual general meeting change control defensive measures ernst young ltd received following remu articles incorporation contain provi neration services auditors sions mandatory bid rule swiss law genentech chugai applies changeofcontrol clauses components remuneration based roche millions chf nes would terminated event genentech chugai audits acquisition vesting period restrictions consulting services provided preexisting awards would removedso genentech chugai options could immediately exercised total relationship group auditors information policy statutory auditors provided articles incorpora annual general meeting roche hold tion corporate notices published ing ltd february shareholders swiss official gazette commerce voted appoint kpmg klynveld peat marwick daily newspapers designated board goerdeler sa kpmg group auditors directors basler zeitungfinanz und wirtschaft statutory auditors information long lagefile tempsneue zrcher zeitung current group auditors principal auditor roche reports halfyear fullyear results serving capacities provided business reports published print online group auditors statutory formats media events addition auditors participate audit committee meet detailed first thirdquarter sales figures ingsthe auditors make written oral reports published year april october results oftheir auditsthe audit commit current list ofpublication dates available tee oversees assesses auditors makes english german internet recommendations board information relevant information documentsinclud responsibilities audit committee ing media releases investor updates see article bylaws group presentations analyst investor conferences auditors statutory auditors participated available internet publica four meetings ofthe auditaudit corporate tions ordered emailfax telephone governance committee baselwebmasterrochecom reports ofthe group statutory auditors tel fax found respectivelyof years finance report httpwwwrochecomhomecompany comgovcomgovbylawshtm kpmg received following remuneration httpwwwrochecomhomecompany services group auditors statutory comgovcomgovartihtm auditors roche holding ltd roche httpwwwrochecomhomemediamedeventshtm financial companies httpwwwrochecomhomeinvestors invnewsupdhtm business report corporate governance contact address investor relations fhoffmannla roche ltdinvestor relations corporate finance baselswitzerland tel fax additional information including details specific contact persons available internet compliance officer compliance officer committed ensur ing roche corporate principles consis tently complied throughout roche group also serves contact person shareholders employees customers suppliers general public issues relating implementation compliance principles employees parties become aware violations roche corporate principles bring attention managers supervisors report compliance officer andreas greuter direct phone number email andreasgreuterrochecom disclosures treated confidential employees make disclosures penalised company sobut immune prosecution legal violationsthe com pliance officer reports regularly corporate governance sustainability committee nonapplicabilitynegative disclosure expressly noted information contained mentioned herein nonapplicable omission construed negative declaration according requirements ofthe swx swiss exchange corporate governance directiveincluding commentary httpwwwrochecomhomeinvestors invcontacthtm business report remuneration report remuneration report roches success depends abilities dedica stocksettled stock appreciation rights tion ofits peoplerecognition ofthis founda tion ofour remuneration policy systemin stocksettled stock appreciation rights ssars remuneration report inform shareholders introduced roche january thus interested members ofthe general public establishing uniform system remuneration remuneration paid directors senior throughout rochessars entitle holders bene executives integral part annual fit financially increase value reportthis remuneration report submitted roches nonvoting equity securities approval annual general meeting grant date exercise datedetailed informa tion available remuneration policy performance share plan roche revised global remuneration policy part ofa framework ofemployee policies members ofthe corporate executive commit aimed motivating retaining current employ tee members senior management ees attracting talented new ones helping individuals worldwide participate roche employees perform consistently high performance share plan psp estab levelsour remuneration policy designed fos lished beginning periods ofthree ter value creation reinforce culture per years first performance cycle ended formance innovation applies non second cycle psp managerial employees well managerskey third year principles underpinning policy starting adjusted plan design intro focus value creation ducedunder new arrangements onethird pay performance many nonvoting equity securities nes enabling employees share companys awarded new threeyear performance cycle success starts yearin contrast successive three fairness transparency remuneration year cycles old plan designin decisions thus two overlapping performance cyclespsp remuneration targeted market median levels psp however balanced mix oflong shortterm remu increase total awardfor details ofthe psp neration components see marketcompetitiveness five years since psp established awards stocksettled stock appreciation rights roche securities shares nesincluding performance share plan support prin dividend yields almost doubled value ciplesthese remuneration components linked outperforming ninefold value growth companys financial performance com delivered peer set major pharmaceuticals mercial success thus align interests diagnostics companies roche employees ofthe stockholders peer set abbott laboratories amgen astrazeneca bayer beckton dickinson biogen idec bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck novartis pfizer sanofiaventis scheringplough takeda wyeth business report remuneration report tsr development december value chf invested st week january period ending december prices translated constant chf exchange rates remuneration corporate executive remuneration additional compensation paid committee nonexecutive members board directors totalled swiss francs previous remuneration committeewhich comprised year swiss francswith exception entirely independent external members two vicechairmen independent lead board ofdirectorssets remuneration mem directorall members ofthe board ofdirectors bers corporate executive committee cash received remuneration since payments bonuses options stocksettled stock appreciation rights policy decisions pen nonexecutive members ofthe board ofdirec sion benefitsthe terms ofthe performance share tors awarded shares nonvoting plan determined board directors equity securitiesstocksettled stock appreciation acting upon recommendations remu rights stock options neration committee december held unvested options awarded previous years following detailed review including market comparisons remuneration committee addition rolf hnggi received pro rata concluded roches current remuneration amount swiss francs serving policy continues appropriate suitable board directors january february achieving intended objectives mr hnggiwho nonexecutive direc torresigned board following pages provide detailed information remuneration paid member john bell oneyear sabbatical leave board directors member university oxford since august corporate executive committee together spending year rocheroche pay figures previous years personal family expenses profbell incurs relation stay switzerland including remuneration insurance costs expenses totalled swiss francs remuneration members board directors members board directors received remuneration shown table serving board business report naj rpa yluj tco naj rpa yluj tco naj rpa yluj tco naj rpa yluj tco naj rpa yluj tco ced roche nes roche share peer set price price index see stock optionsstocksettled stock appreciation rights remuneration report remuneration members board directors additional compensation remuneration members remuneration committee members board directors chf chf fb humer b gehrig hoffmann ji bell p brabeckletmathe ljr de vink w frey da julius oeri h teltschik b weder di mauro total swiss francs per committee membershipyear except members presidium vicechairmen remuneration paid fb humer executive member board directors deducted agreed salary see remuneration members corporate executive committee remuneration serving independent lead director vicechairman board prorated remuneration serving member board directors january february vicechair man board period march december prorated remuneration period march december remuneration members corporate executive committee cash payments chf annual salary annual salary annual salary bonus bonus bonus fb humer wm burns e hunziker ga keller jkc knowles schwan total b stock optionsstocksettled stock appreciation rights ssars ssars ssars stock options value chf value chf value chf fb humer wm burns e hunziker ga keller jkc knowles schwan total see stock optionsstocksettled stock appreciation rights blackscholes value described stock optionsstocksettled stock appreciation rights business report remuneration report roche paid swiss francs retirement members corporate executive committee policy john bell additionally receive annual expense allowances swiss francs chief executive officer horst teltschik received honoraria including receives annual expense allowance expenses amounting euros swiss swiss francsin members ofthe executive francs serving boards several roche committee received expense allowances totalling subsidiaries germany swiss francs otherwiseno additional remuneration paid heino von prondzynski stepped members ofthe board ofdirectors corporate executive committee december assisted transition remuneration members successorheino von prondzynski resigned corporate executive committee roche effect december general provisions assigning authority deci paid salary swiss francshe sions corporate executive committee remuner received bonus swiss francs respect ation remuneration committee expense allowance swiss board directors outlined francs remuneration report c performance share plan members corporate executive members ofthe corporate executive commit committee received salaries bonuses stock tee members senior management optionsstocksettled stock appreciation rights individuals worldwide participate nonvoting equity securities shown tables performance share plan psp performance share plan psp total estimated total estimated value psp awards value psp awards target number target number nes psp nes psp chf chf fb humer wm burns e hunziker ga keller jkc knowles schwan total estimated value calculated using yearend price december chf per nonvoting equity secur ity nes based number nes originally targeted subject changes number value nes awardable plan december spread relevant period time ie year board directors vote actual allocation nes originally targeted december according tsr growth achieved estimated value calculated using yearend price december chf per nonvoting equity secur ity nes based number nes originally targeted subject changes number value nes awardable plan december spread relevant period time ie year board directors vote actual allocation nes originally targeted december according tsr growth achieved estimated value calculated using yearend price december chf per nonvoting equity secur ity nes based number nes originally targeted subject changes number value nes awardable plan december spread relevant period time ie year board directors vote actual allocation nes originally targeted december according tsr growth achieved business report remuneration report roches performance roche tsr average tsr peer group companies jan dec jan dec total shareholder return tsr value chf invested january roche market capitalisation billions chf roche securities chf nonvoting equity security nes share prices translated constant chf exchange rates tsr stock price appreciation plus dividend psp moved overlapping threeyear bers corporate executive committee performance cycles new cycle beginning shown table board ofdirec year thus two cycles tors decide actual level nes cash progress psp psp equivalent awards cycles provisions ofthis plana number ofnon close voting equity securities nes reserved financial yearsrespectively participants cycle number securities actually awarded depend whether end two years one yearrespectively extent investment roche securi psp psp per ties shares nes outperforms average formance cycles based threemonth return investment securities issued moving average constant exchange rates roche peer set ofcomparator companiescomparisons ranked compared peer set based securitiesmarket prices divi companies operating industry dend yieldsieon total shareholder return tsr reduce effect ofany shortterm market fluc roches market value rose billion tuationssecurity prices averaged three billion swiss francs period january months october december prior start december increase billion performance cycle three months swiss francs dividends totalling bil october december end cycle lion swiss francs billion swiss francs roche securities perform well better billion swiss francs distributed peer set addition roches tsr increases least cycle indirect benefits board directors elect increase employer contributions made maximum nes award much twofold social security schemes pension plans event investment roche securities underperforms average return delivered peer companiesfewer nes awarded nes reserved plan mem business report see footnote see footnote remuneration report indirect benefits pension fundsmgb ahvivalv roche connect chf chf chf fb humer wm burns e hunziker ga keller jkc knowles schwan total mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits ahvivalv swiss social security programmes providing retirement disability unemployment benefits owing amendments switzerlands federal occupational old age survivors disability pension act bvg contri butions behalf franz b humer limited swiss francs existing contractual obligations result additional provision swiss francs company groupwide employee stock purchase plan roche pensions totalling swiss francs paid connect respect members corporate two former corporate executive committee executive committee shown table members indirect benefits franz bhumererich hunzikerwilliam mburns roche connect voluntary stock purchase plan jonathan kcknowles received total usd offering employees opportunity buy roche swiss francs serving nonvoting equity securities nes amount chugai board erich hunziker william burns equal oftheir annual salary discount jonathan kcknowles genentech nes purchased plan subject hold board declined remuneration serving ing periodwhich switzerland four years capacity roche paid swiss francs occupational otherwise additional remuneration paid pension contributions swiss francs current former members corporate employer ahv social security contributions executive committee swiss francs roche connect contribu tions heino von prondzynski f highest total remuneration chairman ceo franz bhumer mem e remuneration emoluments loans ber ofthe board member ofthe corporate corporate officers executive committee highest total remu neration see remuneration members gottlieb keller repaid mortgage loan corporate executive committee fhoffmannla roche ltd pension fund subject changes allocations computations end relating threeyear performance share plan psp periods franz b roche paid severin schwan swiss francs humers salary follows foronetime relocation housing costs business report remuneration report highest total remuneration chf cash payments stock optionsssars blackscholes valueat grant minus performance share plan pension fundsmgb roche connect total value blackscholes value described stock optionsstocksettled stock appreciation rights see see remuneration members corporate executive committee c performance share plan psp estimated value psp psp cycles paid estimated value psp cycle paid value year psp cycle mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits including provision see footnote payments pension schemes including annual expense allowances remuneration serving chugai board usd chf shareholdings nonexecutive members ofthe board ofdirec directors andr hoffmann andreas oeri tors persons closely associated members founders families closely members ofthe executive committee per associated belong shareholder group sons closely associated held shares pooled voting rightsat end shown table group held shares issued sharesandr hoffmann serves spokesman stock optionsstocksettled stock shareholder groupdetailed information appreciation rights group found finance report december members corpo note roche group consolidated financial rate executive committee held options stock statements related parties settled stock appreciation rights ssars first notes financial statements ofroche holding introduced january shown ltd additionas december table shareholdings december members corporate members board directors number shares executive committee number shares fb humer wm burns b gehrig e hunziker hoffmann ga keller ji bell jkc knowles p brabeckletmathe schwan ljr de vink w frey da julius oeri h teltschik b weder di mauro total total figure include shares held shareholder group pooled voting rights business report remuneration report stock options ssars number stock options ssars held members corporate executive committee december ssars first issued total number strike price chf expiry date grant value per option starting per ssar chf blackscholes value minus ssars options shown table issued using blackscholes formula roche employee stock options option options tradablewith deduction entitles holder purchase one roche non average twoyear vesting period voting equity security nes strike pricesexpiry dates grant values terms ofthis multiyear option planthe options ssars shown table strike price options shown closing numbers options ssars calculated price roche nes last day oftrading prior time issue entered values roche annual media conferenceall table remuneration ofmembers ofthe corpo options shown nontradableonethird rate executive committeebstock optionsstock options subject vesting period one year settled stock appreciation rightson onethird vesting period two years onethird vesting period ofthree yearsunvested options lapse without compensation employ ment terminated voluntarily reasons retirement vested options must exercised within limited period timethe fair value ofthe options calculated date ofissue using blackscholes formula options tradablewith deduction average twoyear vesting period ssars shown table intro duced roche january place ofstock options ssars entitle holders benefit finan cially increase value ofroches nes grant date exercise date strike price ssars terms multiyear plan closing price roche nes first day trading roche annual media conferenceall ssars vest within three years grant date ieonethird vest end one year onethird end two yearsand onethird end ofthree yearsvested ssars must exercised converted nes within seven years grant date unexer cised ssars lapse without compensationthe fair value ofthe options calculated date ofissue business report doctor hadnt thought id never known hep c business report identifying early respondershelps motivate patients difficulttocure hepatitis c alain lacroix public relations manager paris public transport system routine screening company doctor revealed hepatitis c virus hcv infectionthe source infection traced gastric biopsy hed theyear beforealain recalls shocki felt lowhe sayswith sorts questions mind normally outgoinghe found drawingworried passing infection toothers alains viral genotype difficulttocure b starting treatment standard interferon ribavirin april nothing side effects show month course three painful injections week still virus october alains hepatologist started himon onceweekly pegasys pegylated interferon alfaacombined copegus ribavirin shetracked effect oftreatment using amplicor hcv testafter weeks virus gonesays alainrecalling elation learning afast response gave chance lasting cureits stayed like ever sinceim extremely grateful researchers found answers thisdisease source infection virtually eliminated revised operative procedures diagnosis therapy monitoring sensitive tests needed diagnose hepatitis c potentially fatal disease symptoms monitor treatment response early responders therapy pegasys copegus enjoy good chance cure reliable measurement viral load must today roche offers even sensitive realtime pcr monitoring tests cobas taqman platform better enable doctors confirm hepatitis c clearance business report creating sustainable value management approach business integral part society providing roche good position respondour busi essential productsjobs economic bene ness strategy see based creating fitsthe success ofcompanies largely determined value patients employees shareholders well contribute society much society focusing innovative healthcare solu value create offering needed products tions unmet medical needs services nowhere relevant healthcare management model sectorwhere products active core sustainability peoples lives ensuring health well beingwe perform essential function society minimumroche runs business compli obtain licence operate ance national international lawsas well continue business must create sustainable voluntary guidelines set nongovernmen value ofour key stakeholders tal organisationsoften corporate standards go beyond requirementsat rochesustainabil responsible prod ity integral part ofour daily businessit ucts servicesincreasinglystakeholders demand managed astandalone departmentbut manage impacts people envi network people representing aspects ronment actively contribute wider society company allowing involvement engagement means every step take many levels sustainability priorities consider broad range offactors influence goals found table businessover past decades become even important complex corporate sustainability management model business report creating sustainable value management approach managing risk identify relevant sustainability issues arising business model expectations variety risks expose roche pressures ofour key stakeholders could prevent us achieving goals analyse link issues roche group manages risks identifying economic success themevaluating significance decid develop relevant key performance indicators ing action take part process kpis identify social environmental ethical risks embed kpis existing business processes see take action mitigate risks possible throughout roche group established risks monitored findings present strong business case sus business units individually accountable tainabilitywe identified sustainability issues performance risks conduct regular relevant economic success developed risk assessmentsthese fed consolidated afirst draft ofkey performance indicators tomeas annual group risk report discussed ure value company creates main corporate executive committee context stakeholders business plan reviewed audit committee genentech chugai manage major value drivers ofthe issues identified risks independently developing innovative drugs unmet medical needs sustainability business strategy retaining attracting employees business case protecting reputation good business ethics set project define roches busi assuring future success receiving ness case sustainability aim ensure compensation reward innovation sustainability issues fully integrated maintaining licence operate business protect current company value stakeholder acceptance create future value project involves large reducing business risk network people representing aspects improving operational efficiency businessfacilitated corporate sustainability committeethe project four stages roches business model business case sustainability business report creating sustainable value management approach scientific community governments ngos employees regulatory authorities productivity performancesalary inno liv cat eiv nse e h te ilt nh n ovol atut ei ns operate doctors patients trust reputation income roche return investment investors patient groups health benefits capital healthcare payers society suppliers business partners continue develop business case engaging employees sustainabilitythis includes finalising set ofkpis integrating internal reporting end surveyed internal stake planning targetsetting business pro holders employees effectiveness cesses within affiliates also aim use internal communications attitude project findings external sustainability towards companyfurther details found reporting stakeholder engagement pages working customers engaging key stakeholders customers patients benefit stakeholders millions ofpeople around medicines diagnosticshealth authorities world influence interest roche pay healthcare professionals pre include patients medical community scribe administer laboratories employees governments regulators non perform diagnostic testingour products sold governmental organisations ngos share countries improving patients health holders quality length oflife building maintaining relationships communicate patients health groups helps us better understand needs care professionals pass patients views develop business strategy generate max us productrelated websites imum benefits company stake wwwaccuchekcom wwwbonepaincom holdersthe diagram relationships key issuemanagement system patient stakeholdersshows main benefits rela associationsin roche worked number tionships different groups patient associations global regional business report hcraeser cisab slairetam emocni sboj dna emocni relationships key stakeholders income healthcostbenefits taxes jobs donal tii oce nn sse operatecreating sustainable value management approach national level issues important patients time innovest rated us top sustainability healthcare policy patient access healthcare dis ranking global pharmaceutical companies ease awarenesseducation patient information results clearly support integration ofsus maintainclose relationships health author tainability business ities healthcare professionals ensure new products meet legal requirements user needs partnership suppliers pharmaceuticals division carried aim suppliers service providers extensive stakeholder engagement project meet internal standards employment key opinion leaderspatient groupsoncology soci environmental performance well legal etiesclinical trial groups research commu requirements roches internal guidelines explain nitythe project aimed gain global perspective conduct expect companies groups perception roche purchase used basis developing relationships around key suppliers monitor well comply guidelines using dialogue customers provide positive questionnaires onthespot audits keeping negative feedback reality checks particularly close eye workplace safetyindustrial important source ofinformation improving hygienepollution waste management products servicesensuring successful product launches meeting needs ofour customers twothirds suppliers audited theend ofcompliance found accept increasing value shareholders able good ofthemroche working andinvestors remaining help improve standards supplier refuse either audit aim achieve fair valuation business orrequest improvementroche cease communication based principle business fair disclosurewe communicate investors wider financial community help inform web investment decisionsan increasing number investors also seek information environ corporate sustainability committee charter goals mentalsocial governance issues activities wwwrochecomsuscharter access medicines wwwrochecomsusaccess engaged directly investors patient groups wwwrochecomsuspatientgroups annual general meeting customer visits investor relations wwwrochecominvestors roche rocheorganised events annual media wwwrochecommedia halfyear reports investor updates also suppliers wwwrochecomsussuppliers participated broker conferences held employees wwwrochecomsusemployees road shows key markets scientific community wwwrochecomscience andwwwrochecomsusfoundations roches investor relations team ranked governments ngos regulatory authorities health institutional investor amongst best switzer care payers wwwrochecomsusexternalaffairs land pharmaceutical sector irmagazine europe judged investment com munity events best continental europe priority actions across sectors six key priorities see table roche listed healthcare leader dow ensure make maximum contribution sus jones world dow jones stoxx ftsegood tainable development part broad sustainability indexesfor third yearfor first work plan covers everyday activities business report key management topics many ethical social issues extending access medicines integral part impact business must well man healthcarealong preventiondiagnosistreat agedthese include ment monitoringworking governments organisations way increase valueaccess affordability ofour access innovative lifesaving tests medicines diagnostics medicinesthis roche implemented dif retaining attracting top talent ferent programmes partnerships improving business ethics access least developed developed countries responsible marketing conduct ofclinical trials value innovative products patient safety product quality new technologies cancer second biggest killer europe respecting human rights heart disease oncology specialists suggest cost innovative drugs avastin section explains issues roches treatment colorectal cancer prevents importance roche responding doctors using increasing preva lence cancer stretched healthcare budgets debate continue value access affordability howevera focus price drug ignores medical value products provideroches developing products services save innovative drugs avastin herceptin mabthera improve lives greatest contribution roche tarceva xeloda revolutionised way make society countless people cancer treated providing significant benefits developed developing world access millions ofcancer patients improving effi tests medicines need ciency ofhealthcare systemsthese drugs slow progression cancer dramatically improve many developing countries lack even basic quality life even save lives used healthcare facilities well medicines early stage ofthe disease see box need infrastructure health professionals toensure right diagnosis made right increasingly find governments payers medicines get right peopleeducation also grant full reimbursement oncology drugs essential combating spread preventable seen demonstrable benefits infectionsincluding hivaids patients society healthcare systems example based remarkable results early even industrialised nations availability breast cancerpayers several countries taken medicines varies neighbouring exceptional measures reimburse early treatment countriessome patients disease herceptin drug received regulatory able live longerhealthier lives others simply approval live due varying levels access medicines even medicines oftotal healthcare spend medicines availablesome people afford themor diagnostic testsbut use ofdiagnos insurance pay tics combined medicines dramatically increase effectiveness healthcare enabling pre vention early diagnosis treatment treatment business report key management topics priority actions priority goals progress embedding ensure contributing identified businessrelevant sustainability issues analysed links sustainability tosustainable development issues roches economic success part daily work began developing key performance indicators measure progress increases success piloted sustainability risk identification process flag see topics business reselected djsi ftsegood indexes wwwrochecomsusprinciplesobjectives access continue develop new marketing applications filed marketing approvals received healthcare innovative medicines patients participated clinical trials ways increase access people living hivaids covered reduced pricing toour products globally established technology transfer initiative subsaharan africa indeveloped developing andthe ldcs agreements signed least developed tamiflu manufacturing capacity increased years countries wwwrochecomsusaccess ensuring strengthen ethical code conduct elearning programme available ten languages responsible compliance awareness andlaunched countries business roche activities published revised position paper clinical trials practices published details clinical trials trial results independent website phase patient trials seven different medical conditions published first time developed guidelines working patient groups published list key groups website animal testing sites aaalac accredited wwwrochecomsusgovernance wwwrochecomsusresearchdev wwwrochecomsusethics patient safety provide highly effective strengthened safety risk management plan emphasise safe use medicines whose benefits ofroche products maintain positive benefitrisk profile exceed risks updated global website improve transparency disclosure onour minimal adverse drug safety processes reactions wwwrochecomsuspatientsafety retain establish programmes genentech ranked first roche pharmaceuticals third science attracttop talent toretain attract magazines top employers biotech pharmaceutical industries best talent right job roche employees surveyed say proud work roche foster performance key management positions filled internally culture eligible employees participated employee nonvoting equity securities programme introduced new secondment policy enabling employees contribute toprojects developing countries months launched roche engage focuses engage employees business strategy wwwrochecomsusemployees safety implement action plans developed position papers covering key issues health atall sites achieve long developed allocated sitespecific goals contribute group goals environmental term group goals organised global conference focusing risk management protection reduce accident energy efficiency development action plans reach goals absence rates issued group directive energy conservation based international reduce environmental energy workshops including energy efficiency standards equipment impacts installations ensure energy efficiency met fiveyear targets reducing emissions greenhouse gases targets volatile organic compounds vocs sooner planned reduce emissions sites received roche responsible care network award greenhouse gas voc outstanding low accident rates positive trends improve compliance received relevant fines relating roches standards wwwrochecomsusshe business report key management topics need common view nils wilking karolinska institute stock holm sweden discusses research roles governments industry helping cancer patients get treatment need key findings research huge differences european countries amount investment cancer treatments time takes approve new drugs means access treatments vary widely cancer accounts total disease burden europe yet spend ing treatment amounts total health care costs pharmaceutical companies help governments help improve access wider research effectiveness drugs cancer treatments market would also help underline cost pharmaceutical companies develop innovative effectiveness companies like roche provide drugs healthcare systems integrate information doctors value new drugs drugs therapy programmes ensure help make sure offered patients need patients access authorities individual countries currently making isolated decisions universal evaluation procedure homogeneous go reimbursement process would provide common view innovative drugs present enormous opportunity effectiveness drug help speed treat diseases unmet medical need approval process availability onto market interests healthcare providers pharmaceutical industry patients alike recognise value innovative new drugs increase access paneuropean comparison regarding patient access groups must continue work together cancer drugs karolinska institute achieve common aim monitoring brings great cost benefits programmes often includes additional health benefits increasing respon treatment testing normally sibility demonstrate medical receivedwhere necessary continue provide economic benefits products bring drugs free charge product com mercially available enabling global access hospitals clinics worldwide sell products services compensated patient taking part roche countries customers access trialsthis money often used fund additional regular channels clinicians nursing staffeducational centres research practicespharmacies hospitals otherwise would possiblephase ivor post approval trialsallow clinicians become familiar provide free medicines testing patients new drug safety profile prior involved extensive phase iiv clinical trial widespread availability business report key management topics united states support several patient continue research development new assistance programmes providing free medicines hivaids medicines people need inadequate promote educationtraining knowledge health insurance include roche sharing patient assistance programme partnership donate technical expertise local service prescription assistance providers manufacturers genentech access care foundation patents pricing hivaids medicines genentech endowment cystic fibrosis provide free medicines eligible uninsured many million people living underinsured patientsin october genentech disease subsaharan africaimproving access announced doubled contribution hivaids treatment remains priority independent charities provide financial assis tance medical treatment ofeligible patients roches policy enforce existing patents genentech unveiled plans begin first apply new patents medicines ofitskind programme cap overall cost least developed countries ldcs avastin usd per year per eligible sameapplies hivaids medicines sub patient fdaapproved indication saharan african countrieswe supply protease programme available eligible patients inhibitors invirase saquinavir viracept nelfi regardless whether insured navir noprofit prices ldcs company anticipates launch new subsaharan africa lowest prices programme first quarter medicines viably made available long termroche also supplies drugs patients benefiting access free roche group reduced prices countries defined world products bank low lower middleincome number patients actively participating phase iiv trials worldwide noprofit pricing applies mil number patients benefiting lion people countries covering patient assistance programmes people living hivaids increases united states include reduced prices charged total low lower middleincome countries programmes least developed countries patients covered roches pricing policy hivaids patients living ldcs healthcare needs people different coun subsaharan africa tries communities hugely varied hivaids patients living low provided single approach lower middleincome countries assessing need responding appro total priately make difference playing active role primary role improve discover innovative medicines unmet needswe also constantly striving neweffective ways implemented programmes help people living increase access products services poorest countries hardest hit certain includes number ofprogrammes expand access diseases strategy improving access hivaids treatment developing world medicines developing world examples clear patent pricing policies rather donating products ldcs defined united nations found build partnerships governmentsngos httpwwwunorgspecialrepohrllsldclisthtm committed parties business report key management topics sharing manufacturing know countries need luc schnitzler technical expert roches technology transfer initiative tti roches technology transfer initiative tti launched january help compa nies manufacture generic versions hiv medicine invirase saquinavir least developed countries subsaharan africa people hivaids live countries different companies rather offering voluntary licences selected companies roche offers free onsite technical assis evaluation criteria use ensure companies tance appropriate local manufacturers eligible work produce saquinavir safely countries patent policy means licensing unnec currently comply recommend improve essary believe offers value local com ments reassess future panies often knowledge infrastruc ture start production quality medicines must meet local standards sup job involve port local manufacturers wherever possible ulti role assess capabilities interested com mately manufacturer responsible quality panies provide technical knowhow generic medicines eligible companies expressed interest manufacturing saquinavir three agreements confident programme suc place south africa kenya cess yes strong interest shows important companies suffi manufacturing knowhow areas hit hardest cient capability hivaids highly motivated succeed technology transfer initiative see box three noses made subsaharan africa infants agreements technologysharing reached exposed hiv patients within nine months january launch region hivaids treatment monitored discussions continue companies countries cambodia treatment access programme ctap publicprivate partnership increased amplicareviral load tests allow doctors moni availability hivaids therapies provides tor precisely progression patients hiv local training healthcare professionals since infection modify treatment keep drug resis launch programme enrolled tance control amplicare local patients provided hivaids training authorities hospitals built equipped cambodian healthcare workers laboratoriestrained lab workers diagnosed september opened permanent treatment monitored patients diag centre capitalphnom penh business report key management topics care partnership roche implemented elearning programme pharmaccess foundation helped make behaviour business roches principles hivaids treatment sustainable strengthening guidelinescode conduct strengthen local health systems training african healthcare awarenessthe programme available ten lan workersin hosted fourth care man guagesand rollout completed early agement exchange workshop training meeting target participation rate least healthcare workers african coun excluding employees chugai genentech triesthe event provided valuable insight us affiliates compli real needs people involved fight ance programmes hivaids africathe findings submitted publication global initiative increased compliance awareness leading higher number alleged division tropical diseases compliance failures referred compliance offi ran series workshops auditing quality cerout alleged compliance failures cases assurance researchers managing moni required corrective action including termination toring trials tropical diseases also ofemployment contractsin continue audited trials ofleishmaniasis supported raising awareness code conduct training events subsaharan africa asia emphasis local training initiatives web ethics research development access programmes partnerships ethical concerns often arise developing new wwwrochecomsusaccessprogrammes medicines diagnostics groundbreaking sci hivaids patent pricing policies ence stem cell research brings great benefits wwwrochehivcom also presents risks comes responsibil roche patient assistant foundation ities wwwrocheusacomprogramspatientassistasp roche clear position ethical issues retaining attracting top talent affecting researchwe updated global posi tion statement clinical research september business strategy based innovation comprehensive document explains employing engaging best people key policies includes information clinical trials knowledgebased businesspeople work developing countriesprotection genetic data pharmaceutical industry want employer publication trials web databaseall offers clear strategy innovation chance policies position statements found tomake differencedetails retain website attract talented employees found sec tion peopleon employees inevitably come across ethical con cerns work clinical trialsifthese resolved within team employee business ethics contact global ethics liaison officeifa query satisfactorily resolved process code conduct compliance factfinding consultation peers appro priate subjectmatter experts may referred corporate principles describe company internal committee experts want one employees proud work stilluncertaintyan independent external advisory partners trust principles com groupthe clinical research ethics advisory group bined directivesguidelines policies creag may consulted specific areasform code ofconduct total queries brought global business report key management topics innovative use technology refine reduce animal studies research markus von kienlin hansruedi loetscher preclinical imaging department basel explain magnetic resonance imaging mri helping strengthen pipeline reducing number animals needed mri reduce need animals mri uses magnetic fields create images body harm animal way means animal imaged many times changes time monitored reduces therapeutic areas mri used total number animals needed addition imag roche wide range animal models cns dis ing data often reliable measuring orders use mri identify patterns brain activity animals beginning study usually associated disease effects treatment leads improved statistical outcome wealso use mri measure efficacy com pounds animal models metabolic diseases advantages using mri diabetes mri noninvasive monitors physiological pro cesses living unperturbed organisms mri use mri give roche compet applied humans well animals allowing itive advantage direct comparison findings particularly use feel edge combining ful disorders central nervous system cns advanced mri technology sophisticated ani mri unique tool bridge preclinical mal research particularly cns disorders research animals early clinical development commitment extend mri clinical studies humans humans translational medicine ethics liaison office resolved none mous samples ensure patient confidentiality required escalation redesign ofpatient consent forms make clearer key topics addressed creag meeting included policy transparency clinical responsible animal testing trialsand review recent cases brought global ethics liaison office roche takes public concern use ani mals scientific research seriously second independent panelthe science ethics support efforts find alternatives including advisory group seag provides roche external organisations swiss rs foun guidance advice counsel issues broadly dation replacereducerefinein plan related geneticsgenomics proteomicskey establish roche rs awardto stimulate topics discussed included use ofanony internal efforts area business report key management topics use animals results active member major industry associa obtained without thembut animal experiments tionsroche contributes reviews oftheir codes sometimes suitable way identify side practicethese include efpia code ofpractice effects often legally requiredwe use promotion medicines last reviewed test causes animal least distresssuch november revised ifpma code noninvasive magnetic resonance imaging see box pharmaceutical marketing practices came force january designed animal welfare audit check list contractors goal encourage general manager roche affiliate discussion within industry independent responsible ensuring compliance auditing possibly involving animal welfare organ national code practicewhich based either isations ofcontractors specialised animal ifpma efpia codeand applicable laws experimentation companies marketing pharmaceuticals compliance monitored internal audit team com animals used pliance officer research mice rats nonhuman primates animals used research strongly believe patients carried contractors represent less active role decisions regarding health ofall animals used roche group wellbeingto ensure thiswe work alongside patient groups share aim provide new expect testing sites received effective safe treatments quickly system accreditation association assess atically possible ment accreditation oflaboratory animal care aaalac end introduced set ofguidelines working patient groups february aim cre web ate genuine mutually beneficial partnerships reflect common values integrity indepen roche corporate principles code conduct dencerespect transparencythey specify wwwrochecomsusprinciplescodeconduct work carried must benefit patients repre clinical research ethics advisory group sented groupand groups wwwrochecomsuscreag asked endorse specific product see box science ethics advisory group wwwrochecomsusseag protecting intellectual property animal welfare wwwrochecomsusanimalwelfare adequate protection innovation essential policy position papers industry ifwe continue finding new diag wwwrochecomsuspoliciespositionsguidelines nostics drugs fight diseases cancer alzheimersdiabetes hivaids responsible marketing pharmaceutical companies patent new drugs make sure recoup investmentby patients right factual information sole manufacturer ofa drug limited medicineswe follow external guidelines codes period usually eight ten years companies practice marketing pharmaceuticals motivated ensure process innovation include world health organizations ethical interrupted continue bringing new criteria medicinal drug promotion also improved medicines market internal guidelines design use promotional materials activities comply file patents worlds least developed regulations concerning advertising directly countriesto ensure patients prevented consumer receiving roche medicines due patents business report key management topics working effectively patient groups jean mossman former ceo leading uk cancer support charity cancerbackup helped roche develop guidelines working patient groups ensure patients opinions taken account companies patient groups best work together patients want access effective treatment industry wants commercialise products com mon agenda get right treatments right patients right time patient groups companies best achieve effective partnerships sides equal compa byunderstanding others perspective longterm nies see contribution valuable partnerships provide mutual benefit patient group must try influence groups agenda try put benefits company patients brand patient groups products companies society general also ensure relationships dont suffer patients often dont take medicines directed mak changes personnel ing treatment ineffective input patients ensures information drugs simple clear com codevelop guidelines working panies better understand experience patient groups roche living disease matters patients roche recognised various teams working also see drugs fit whole treatment patient groups different ways common plan approach needed asking draft guide lines roche ensured though use companies avoid working employees reflect needs patients patient groups patient organisations counterfeiting poses health risks ment customs officials utmost tackle problem statement fake pharmaceutical diagnostic products counterfeiting available website infringement intellectual property rightsbut importantly endanger lives biosimilars wellbeing patients fakes cause serious illness death ifthey contain harmful ingredients several innovative biological medicines reach deprive patients ofproper treatment end oftheir patent period next years introduction products claiming responsibility preventing controlling drug similar original likelythese known counterfeiting rests primarily national gov biosimilars followon biologics manu ernments international organisations roche facture ofboth active substance finished cooperates worldwide regulatorslaw enforce product requires high level quality control business report key management topics ensure clinical safety approval biosimilars concerns clinical trials developing requires set guidelinesand con countries may carried stan tributing development dard developed world roche employs ich gcp minimum global standard web roche trials introduced additional policies conducting clinical trials low marketing guidelines middleincome countries support wider wwwrochecomsusmarketing global position clinical research guidelines working patient groups wwwrochecomsuspatientgroups support training good clinical practice sub global patent function wwwrochecomsuspatents saharan africa quality assessments asia counterfeiting wwwrochecomsuspatents forum ethical review committees biosimilars wwwrochecomsusbiosimilars asia western pacific region fercap roches clinical trial protocol registry conduct clinical trials trial results database medicines released evidence publish data clinical trials safety effectiveness must provided using people benefit findings welldesigned controlled clinical studies online clinical trial protocol registry results database see address provides information clinical studies roche conducted com new trials key results completed pliance international guidelines must phase iiiv trialsboth registry andthe database approved regulatory authorities include hosted independent company food drug administration fda european agency evaluation medicinal details clinical trials trial results products emea ethics committees local published website since launch institutional review boards april people accessing databasethis includes studies boards ensure proposed trials acceptable breast cancer anemia hepatitis participants fully informed benefits addition december roche trials risks related participation posted us national institutes investigators take appropriate actions protect healths global registry wwwclinicaltrialsgov patients harm following requests patient groups recom framework discussing resolving eth mendation whoand consultation ical issues clinical research together clinical research ethics advisory group creag good clinical practice toolkit provide post information phase trials con involved ensure trials pharmaceutical ducted patients posted year datein seven products meet international conference har different medical conditionsthis enables patients monisation ich internation serious diseases seize albeit small allyrecognised standards good clinical practice opportunity find new treatment solution well local laws web guidelines available intranet employees working trials trained global position statement clinical research required follow themall trialsand processes resolving ethical issues clinical trials systems used conduct themare audited developing countries pharmaceuticals division quality assurance wwwrochecomsusclinicalresearch team clinical trial registry wwwrochetrialscom business report key management topics ensuring patient safety firms safety effectiveness products product quality marketplace giving us early indications potential product issues helping us take users medicines diagnostics preventative action right expect every effort made ensure safety roche systematic processes collect early plan update website ingreporting analysing data ensure patient include detail patient safety product safety throughout product lifecyclein full com quality related procedures pliance local regulations web work hard protect patients potential adverse reactions drugs examine patient safety reported adverse events identify related wwwrochecomsuspatientsafety product might incidental useof risk management procedure productadverse reactions identified early wwwrochecomsusriskmanagement possible classified terms severity whether risks outweigh benefits position new technologies drug safety department works roche affiliates monitor drugs new technologies offer great opportunities launched reporting suspected medical advances development use adverse reaction roche mandatory also create legitimate social concerns phase iiii trialsonce drug launched reason continuously monitor evaluate rely patients healthcare professionals discuss use ofdeveloping technologies authorities soemployees must immediately report information suspected adverse biotechnology uses living organisms make event quality issue drug safety depart modify products processes specific use ment applications biotechnology include genetic engineeringgene stem cell therapyroche risk management procedure ensures patients currently carry stem cell research relevant authorities informed promptly adverse reaction confirmedmany biotechnology also potential replace health authorities require us report serious certain chemicals drug manufacture adverse reactions within daysour country making processes safer environmentally manufacturing sites also subject health soundin published new position paper authority inspections safety health environmental aspects biotechnology paper nanotechnology pharma manufacturing standards lay rules currently drafted tightlycontrolled procedures ensure high quality standards compliance external web regulationsthey cover aspects business include comprehensive safety data review roche position paper biotechnology process ensures new information wwwrochecomsusbiotechnology receive drug assessed product infor roche charter genetics mation updated necessary wwwrochecomsusgenetics science ethics advisory group diagnostics division ensures product design wwwrochecomsusseag production release postmarket surveillance embryonic stem cells therapeutic cloning activities meet regulatory customer require wwwrochecomsusstemcell mentsour global complaint handling system con bioprospecting biodiversity wwwrochecomsusbiodiversity business report key management topics unlocking breakthrough potential avastin peter wenner franchise director avastin roches revolutionary cancer treatment avastin launch successful avastin significant advance cancer treatment first antiangiogenic agent con sistently improve chances survival metastatic colorectal lung breast renal cell cancer limited side effects authorities recognise consider able benefits avastin brings patients granted reimbursement drug record time use colorectal cancer treatment since first launch february approved gramme unlock potential drug countries used patients recruited trials people expected take part trials lifecycle drug avastin developed different types ofcancer parallel isnt unusual roches unique lifecycle management struc normally drug must shown work effectively ture contributed success product one indication developed another roche absolutely lifecycle teams include individuals genentech took bold step conducting trials fromevery key function organisation research avastin pancreatic prostate ovarian cancer development manufacturing regulatory marketing atthe time continuing trials colorectal lung dedicated one product goals unlock breast renal cell cancer result avastin potential product benefit patients approved within short timeframe metastatic maximise value brand colorectal cancer waiting approval use metastatic breast lung cancer lifecycle management structure close cooper ation roche genentech contributed addition twelve phase iii trials currently avastin enjoying one fastest launches underway part extensive development pro oncology product date respecting human rights web roche believes firmly universal human respecting human rights rights declared united nationsour group wwwrochecomsushumanrights employment policy prohibits discrimination group employment policy harassment forced child labour wwwrochecomsusemploymentpolicy grounds respects employeesright join legally recognised employee association fur ther information commitment human rights website business report ive got life back children got father back business report neweffective treatment option people withrheumatoid arthritis steve robsonfrom bedford ukwas hefound rheumatoid arthritis ra onassignment companya specialist piping contractorhe suddenly developed severe pain hishands working jackhammer part day worsening pain swelling hands feet shoulders soon made everyday tasks like tying shoelaces difficult impossibleeven walking became unbearableno longer able hard physical worksteve fortunate employer offered transfer office job two years diagnosissteve needed hip replacementbecause disease destroyed jointfor nine years tried variety treatments none worked longin rheuma tologist enrolled clinical trial mabthera rituximab since first course mabthera three years agoand two subsequent coursessteve pain free joint swelling reducedhe walk comfortablydo household choreswork thegardenand even play football children understandable describes discovering mabthera like winning lottery saysi wouldnt swap winning lottery therapy selectively targeting b cells play key role ra mabthera interrupts series reactions process leads joint inflammation cartilage loss bone erosion characteristic disease patients ra treated mabthera clinical trials date mabthera marketed us genentech biogen idec brand name rituxan business report people brief employment policy sets commitment employees expectations ofthemit new jobs created lines objectives practices aspects million swiss francsremuneration paid people management including talent attraction genentech ranked first roche pharmaceu recruitment performance management develop ticals third science magazines top employers ment compensation diversity discrimination biotech pharmaceutical industries zero tolerance child labour freedom asso various national employer ofchoice ciation health safety environmental awards protection ofemployees surveyed proud work roche total employees fulltime equivalent fte regretted losses employees participating roche con number employees nect nonvoting equity securities programme hours oftraining per employee employ people countries around employees fte operating divisional group world roche created new jobs increasing total workforce roche pharmaceuticals chugai roche business strategy based sustained genentech innovation growthour main source ofinnova tion comes talented individuals within companytherefore ability retainattract recruit talented motivated employees isvital continued business successto retain diagnostics peopleit essential successfully develop skills careers rochewe must also continue attract recruit best talent market enable business grow employees fte region want attractive employer europe staff potential recruits every stage latin america attraction recruitment performancedevel north america opment retention see value chain corporate principleswe state commit ment creating working environment pro motes mutual respect trust integrity asia employees always treated fairly value chain attraction recruiting performance development retention business report people roche engage strategy based executive development roche engage supports strategy provides great insights build maintain culture innovation ursula redeker global head safety technical sciences strategy clearly sets direction com panythe entire roche community must connect androche engage facilitates roy rothenberg finance manager korea must deliver sustained growth value motivat ing inspiring coworkers roche engage changing leadership model one leader time paul nakagaki head research strategy talent attraction recruitment want attract best talent industry one door rocheprogramme launched achieve objective must remain enables prospective employees search employer choice monitor perceptions jobs throughout company website roche employer feedback functiondivision countryjob seekers receive website ratings external surveys personalised email alerts appropriate posi tions become available accumulated continual efforts employer choice global talent pool ofmore external recognised external studies around didates process allowing us build world science magazine voted genen relationships potential recruitssince tech first roche pharmaceuticals third filled positions using system companies top employers biotech pharmaceutical industriesthe survey covered roche keen reach many people pos questions corporate image leadership sible potential employer october direction work culture environment social launched accessibility features career responsibility compensation benefits website improve usability accessibility worklife balance consistently improved people disabilities position last five yearsgenentech held number one spot fifth year running erecruiting halved time takes recruit improves efficiency reduces dropout roche also named employer rate desirable candidates enabling us act choiceby surveys canadachileitalygermany faster competitors also helps increase portugalspain usour australian recruit mobility development opportunities exist ing team awarded best recruiting team ing employees chance work else roche diagnostics germany named best within roche groupby opening employer women full list awards internal job market see received local divisions visit dedicated career website httpcareersrochecom business report people developing talent international assignments monica arosio head international assign ments roche explains roche encourages employees towork abroad develop ment companys roche offer international assign ments roche longstanding tradition promoting sustaining international assignments programmes ever business needs individuals trained deal successfully complex ities different markets countries cultures international assignment con skills everchanging environment like tribute individual company performance enables people reach beyond limits strive international assignment offers unique oppor achieve international assignment tunity exposed unusual circumstances powerful tool develop talent share best practices personally professionally culturally fosters countries come innovative ways greater creativity flexibility adaptability crucial support strategy performance management ment scores areas remained development global employee research company isrs average pharmaceutical sector high success business future performance companies norm roche depends motivated employees work cul pharmaceuticals rolling new global per ture emphasises individual responsibility formance management process across division focusing training feedback employees receive regular feedback performance meet managers individual sites divisions discuss careers performance management training policies meet local needs example programmes place affiliates pharma global informatics rolling career covered total workforce development programme employees similar previous year training totalroche venezuela celebrated development plans agreed first graduation ofstudents threeyear train employees ing course senior sales representatives pharmaceuticals division conducted global addition offering development opportunities survey performance management end existing employees give young people threequarters employees opportunity train apprentices surveyed rated development planning prospect career rochewe currently training positively performance monitoring training apprentices feedback identified key areas improve business report people developing successful careers like fact roche expects efficiency results employees providing fair caring working environment udo bckert head technical services basel company years provided need good job working close contact talented colleagues around world fun enriching experience evamaria gutknecht one first female chemists hired industry roche years global opportunities enjoyed inher three years roche louisa shen worked career roche tremendously broadened arange diagnostics roles switzerland canada perspective work personal life work china always demanding challenging say forcertain never boring day twenty mid toplevel managers asia roche pharmaceuticals introduced new policy pacific diagnostics division took part first enabling employees expand horizons annual apac discovery programme september contribute skills expertise projects twoweek course internationally developing countries taking secondment recognised nanyang business school singapore three months away regular jobs focuses development leadership skills participants selected high leadership roche diagnostics set exchange pro potentialconsistent track record commitment gramme enabling employees departments companygraduates programme germany switzerland us work form pool emerging leaders ensure roches another country continuing success regionrapid growth asiapacific companies underlines need focus developing leadership skills build highlytrained ambitious workforce pool oftalented leaders within roche ensure region future successin launched roche engage new senior executive development programme career roche internationalwe top managers across group keen enable employees broaden programme focuses helping senior leaders experience working countries see box apply leadership skills engaging employees almost employees different countries strategies enabling deliver currently international assignments business goals countries business report people leadership charter sets consistent frame engaging employees work ofleadership competencies essential man agers across company focus providing engage regularly employees assess model ofintegritydriving business successmeeting satisfaction levels gain feedback pro needs ofour customersand motivating employ grammes late surveyed employees ees help improve performance effectiveness internal communications attitude towards companyaround senior middle managers throughout group employees took part response rate set specific goals overall objective almost raising value company perform ance measured ability meet around ofthose surveyed said proud goals contribute increase operating work roche comfortable presenting profit tax capital charges opac roche positive light outside worldfac tors cited make roche stand part succession planning review companies include groups strategy princi potential candidates senior management posi plesits success innovation products tions approximately top across business good working atmosphere motivated managers every yearwe found average succession coworkers appreciation employees candidates position compared social benefits previous yearthis within target range ofto candidates per position global intranet internal newsletters letters corporate executive committee training information meetings keep employees informed companys objectives strategy results total hours invested current research new products addition training employee divisions sites communication development millions channels employees training time days days days per employee hours hours hours pay benefits retention roche committed providing fair compensation benefitsbased local competitive conditions addition personal development opportu employees contribution business nitieswe consider employee satisfaction work total remuneration cost million life balance vital retaining best employees swiss francs total attrition rate permanent staff offer several nonvoting equity securitiesowner proportion regretted losses ship programmes give employees opportu initiated roche nity financial stake companys suc employeeswe arepleased research func cessroche longtermlaunched provides tion source innovation continues consistent approach performancerelated equity see low number departures qualified based remuneration enabling senior managers employees share companys longterm financial growth staff turnover regretted losses roche connect allows employees except usdue legal restrictions purchase non fluctuation voting equity company discounted rate regretted losses around employees eligible participating programme business report people promoting diversity freedom association diversity within workforce invaluable roche respects right every employee capacity innovationon success ofour part ofan employee organisationroche working business dependsroche tolerate discrim open dialogue legal employee represen ination grounds promote people tations countries operate roche three criteria performance potential record individual memberships ofunions functional geographic mobility estimate employees members union employees repre employ people world sented works council similar organisation employees corporate headquarters roche founded roche euroforum repre basel region foreigners represent nation sent employees europe approximately alitiesaround affiliate companies people headed nationals ofwhere company based last year management web teams include consistently high proportion local staff one door roche erecruitment facility httpcareersrochecom want roche attractive employer corporate principles men womenwomen account around wwwrochecomsusprinciplescodeconduct total workforce centrally group employment policy tracked managers senior managers wwwrochecomsusemploymentpolicy weare working attract retain women human rights wwwrochecomsushumanrights proportion women roche local employer choice awards steadily increasing wwwrochecomsusempofchoice httpcareersrochecom gender diversity safety health environment wwwrochecomsusshe women total workforce women management number women top management positions women candidates top management positions recognise healthy worklife balance vital wellbeing performance ofour employees offer range programmes enable employees balance work family com mitmentsemployees choose working pattern suits fulltime parttime flexi time working homewe offer option parttime employment wherever requirements job permitaround employees work parttimeparental leave sabbaticals also arranged worklife balance parttime employees business report communities community involvement described support projects promote new group policy donations noncommer advances basic science encourage young cial sponsorship targeted four key areas people enthusiastic life sciences improve access medicines diagnostics addition local projectswe provide global sup promote advances basic science port research specific areas number education foundations roche organ trans encourage innovation excellence plantation research foundation roche contemporary culture arts foundation anemia research rofarto date support communities employees rofar awarded seven million swiss francs live work research projects around world roche research foundation switzerland gave part civic responsibility also financial support research projects young provides environment inspires employees scientists mba fellowship pro make roche successfulsustainable business gramme provides grants encourage talented scientists complement medical science usually get involved projects qualifications degree business knowledge expertise make significant dif ference prefer work closely local partners parties special expertisewe measure encouraging innovation arts success impact project total amount spent see close links artistic creativity publish detailed figures amount spend innovation activities science community supportwe donate drugs except elsewhere businessroche patron disaster reliefand pandemic situations contemporary arts music centuryas part commitment roche com community support area spend missions sponsors new musical works outstand humanitarian social projects ing contemporary composers see box science education arts culture november roche launched joint project community environment salzburg festivalthe roche continents youth arts science series encourages young people attend contemporary music events access healthcare explore link innovation music art innovation science use expertise improve access health care medicineswe focus efforts roche founded maintains museum benefit greatest needfor tinguely ag baselshowcasing innovative art details please see workrochenjazzlaunched september monthly evening live contemporary jazz music held museum tinguely regularly promoting advances science attended employees members public plan roll local many countries roche driving force rochenjazz events roche sites around scientific community activities world business report communities connecting innovation music science cleveland orchestra partner roche commissions pioneering international project advancement contemporary classical music conductor franz welsermst dis cusses makes partnership work innovation important cleveland orchestra cleveland orchestra stands innovation tradition us tradition means handing things carrying forward involves movement doesnt exclude innovation links innovation music think roche commissions successful science absolutely share common goal aim science music everything discover quality work quantity like roche already exists form find cleveland orchestra known outstanding science takes technical approach research technical ability innovation give new pieces musicians take emotional approach whats music chance heard first time quality fascinating point two meet whether performances highest level organisations developing new medicines composing new also share curiosity future recognise music work create response physical need invest emotional human beings supporting communities founded independent charity roche employee action charity trust react support communities guided help coordinate employee donations employees focusing primarily local projects community supportits goal provide support identified themwe encourage employees play selected sustainable projects charitable part communities volunteering organisations address longterm humanitarian fundraisingroche often match funds needs postdisaster rebuildingespecially raisedoubling total contribution made least developed countries roche began working unicef web support schools malawi attended children orphaned hivaids funding pro group policy donations criteria jects comes annual global roche sponsorship wwwrochecomsusgiving employee aids walksome employees roche drug donation policy sites countries took part december wwwrochecomsusaccess roche matched funds raised roche foundations donate total one million swiss francs wwwrochecomsusfoundations orphans malawi rochenjazz wwwrochenjazznet business report monitor blood glucose every day go hospital month business report monitoring diabetes avoiding complications ceo eschenbach optik japantomio koga demanding job busy scheduleeven sohe manages combine private role asa highschool baseball umpirein private life tomio also shoulder anotherquite different responsibilitywhen doctor diagnosed diabetes routine checkup years agohe deeply shocked conscientiously embarked histherapynever missing appointment hospitalhoweverif managed welldiabetes causes discomfort symptoms tomio gradually forgot illness one point stopped seeing doctor altogether turning point came trip germany colleague told himwhen dia betesyou monitor blood glucose levels regularlyor risk developing cardiovascular complicationswhen explained hard itwas combine frequent checkups schedulehe told could check blood glucose myselfsays tomiohe checks blood glucose levels regularly accuchek compact plus manages data accuchek smart pix means track readings quickly identify deviations apart even faster needing even less bloodmy new meter small easy use particularly important business travel monitoring people type diabetes produce insulin body doesnt produce enough make effective use diagnosis control blood glucose levels adopting healthy lifestyle diet may also inject insulin take tablets products accuchek meters strips enable people diabetes monitor blood glucose accurately conveniently business report safety health environmental protection brief improvements made sites imple mentation necessary actions monitored published new position papers six key enforced strategically important suppliers issues based riskassessment level spend reduction roche accident rate also audited monitor management energy use per employee reduced performance suppliers audited reduction greenhouse gas emissions recommendations improvements inorganic emissions air reduced since implemented safetyhealth environmental protection roche committed upholding high environ separated business success mental safety standards set responsible care fully integrated everything global initiative established chemical employees expected play part pro industry achieve continual improvement tecting environment making roche safe performanceour responsible care network healthy place work communicates commitment standards provides forum sites share advice commitment enshrined roche best practice corporate principleswe revised safetyhealth environmental protection policy late management system covers relevant restate strengthen commitments aspects internationallyrecognised standards international organization stan invested million swiss francs dardizations environmental management stan infrastructure new manufacturing buildings dard iso european ecomanage extension existing installations operating ment audit scheme emasit goal costs including services personnel costs achieve iso emas certification amounted million swiss francs sites nine roche manufacturing sites chosen implement standard voluntarily certified iso three ofthese sites management also attained emas certification responsibility implementing policy awareness continual reduction risks guidelines lies general managers essential prevent accidents incidents affiliate companies individual site managers could affect peoplethe environment busi supported safety environmental ness risks registered evaluated via officer site coordinates cor webbased tool information assessed porate team divisional champions eco group level build global risk profile delegates responsible raising awareness within divisionsin addition regular jobsa total employees work goals fulltime across group set number ofnew longterm quanti roche monitors implementation ofthe policy tative targets global performance adding guidelines directives auditing sites across existing goals group audited higherrisk reduce roche accident rate sites audited oftenrecommendations baseline workdays lostemployee business report safety health environmental protection reduce general absence rate including illness informative accidents made anonymously home accidents published intranet sites baseline days lostemployee made aware potential hazards take reduce total energy consumption action prevent similar incidents baseline gjemployee improve total ecobalance annual roche responsible care network baseline pointsemployee awards recognise sustained outstanding health reduce greenhouse gas emissions safety performance individual sites based baseline co equivalentunit sales roche accident rates previous three reduce voc emissions yearsin sites received award baseline tonnes vocunit sales standing low accident rates positive trends relevant sherelated fines recognise employee wellbeing affected work hourswe started collect occupational health safety data general absences non workrelated accidents assess causes absences safe healthy workplace essential seek possible improvements employeeswellbeing productivityin large research manufacturing operationssafety roche offers range ofprogrammes sites health committees established help promote employee health wellbeing inside safetyhealth environment officer seo raise outside workplace include free awareness organise training implement tech medical checkups workplace ergonomic evalua nical improvements reduce risks work tionscounsellingfitness centreshealthy meals placein smaller sites responsibility lies solely staffrestaurants programmes promote seoin total hours healthy lifestyleswe also several initiatives invested globally training roche promote wellbeing improving employees worklife balance see measure safety health performance using roche accident rate number working days lost due occupational accidents environmental footprint peremployee per yearthe rate decreased development roche roche committed environmental protection accident rate rar showing positive trend throughout lifecycle products iea decreasing number accidentsthe severity research production packaging transport accidentshoweveris going oppo distributionuse disposal site direction ie lost days per accident reported last year concerning occupational measure global environmental footprint diseasesboth numbers recognised cases well using ecoefficiency rate eer ratio lost days per case lower sales environmental impacts expenditure majority cases still referring ecoefficiency described world business locomotor system council sustainable development wbcsd concept creating value less nega health safety tive impact eer takes account wide range offactors energy use emissions roche accident rate air water weighted according signifi occupational accidents cance produce single value higher occupational illnesses eerthe greater degree ofecoefficiencya full workrelated fatalities explanation eer calculated workrelated accidents found website per million working hours business report safety health environmental protection eer increase ofmore nated soil water aspects biotechnology previous yearthe different sources andprevention ofmisuse ofbiological materials ofthis tremendous improvement almost biowarfarethese available website reduction environmental damage par ticular emissions air waterincluding corrections offormer overreportings well energy climate change pleasing development ofthe sales figures global warming climate change well ecoefficiency rate documented greenhouse gas emissions carbon dioxide resulting human activities sales millions chf considered responsible accelerating environmental expenditure global trendsindustry one source ofthese emis millions chf sions must take appropriate measures reduce environmental damage impact international agreements millions environmental kyoto protocoland national legislation define tar damage units gets schedules reducing emissions eer roche supports targets set kyoto pro also calculate ecobalance define tocol reduce global greenhouse gas emissions ecological impact roches operations without working towards goal set considering economic parametersaccording reduce emissions five years method set swiss agency envi close link car ronment bafu ecobalance takes account bon dioxide emissions energy usemost meas outputs environment emissions waste ures reduce energy consumption also decrease use resources raw materials emissionsroche promotes measures energyeach parameter weighted according moving less emissionintensive energy sources significance impactby setting global target applying innovative building technology con improve ecobalance encompassing tinually upgrading infrastructure improve entire environmental footprint individual sites energy efficiencyin roche used tera able identify focus areas joules ofenergyalmost amount make significant improvementsour eco despite business growth balance already matching global target run ecompetition roche introducing fuelefficient lowemission every three years encourage employees think hybrid vehicles fleet corporate cars environment submit ideas reduce emissions transport protection initiatives benefit hybrid vehicles introduced roche environment also cut costs significantly pharmaceuticals fleet usa since similar example introducing measures reduce programme introduced roche energy use airconditioning systems several group member chugai japan added sites entries submitted current hybrid cars fleet bringing total competition launched october employees australia offered hybrid roche responsible care network awards vehicles company cars roche australia reward energysaving initiatives encourage sites begun offset carbon emissions transport help us meet global commitment reduce planting trees area destroyed fire energy use published new global position papers setting strategies affiliates north south america held six key environmental issuesmeeting last years first annual energy conservation summit goal hold public position key topics discuss strategy share best practice public interesttopics covered aregreenhouse gases energy conservation promote message climate changeenergylandfills contami every employee help conserve energy business report safety health environmental protection roche committed phasing halogenated energy use type hydrocarbons potent greenhouse gases ozone depleters cooling systems reduced holdings ofthese gases natural gas tonnes compared gases oil held sealed cooling systems fire extinguish coal ers leakage occurresulting emis waste sions tonnes tonnes renewable energy previous year developed plans replace cooling equip district heating ment containing halogenated hydrocarbons across fuel used business roche diagnostics example company vehicles investing around million swiss francs fuel due business air travel ammoniabased refrigeration plant us head grid electricity quarters indianapolisthe new plant due completion replace current cool ing systems site contain environmentally hazardous refrigerants emissions air measure greenhouse gas emissions volatile organic compounds vocs manu accordance greenhouse gas protocol facturing processes particulates combus taking account direct emissions tion plants contribute local air pollution waste incineration transport power generation smogin roche emitted tonnes ofvocs fossil fuels indirect emissions grid tonnes particulatescompared electricity emissions halogenated hydro tonnes tonnes respectively carbons included co equivalents roche emitted million tonnes co equivalents significant reductions large extent million tonnes due overreporting one main contributor previous years corrected introduced closed systems suitable exhaust roche calculates impact climate change air treatment number sites reduce normalising total emissions expressed co emissions equivalents per million swiss francs sales result decrease nitrogen oxides sulphur dioxide x previous year emissions contribute acid rainroche emit ted tonnes tonnes x total energy use terajoules burning fossil fuels represents low level reduction overall inorganic total energy use emissions previous year total energy use per million chf sales invested million swiss francs mod ernise convert power station supplies greenhouse gas emissions tonnes co equivalents mannheim site germany coal natu ral gas reduced emissions ofnitro total emissions gen oxides nearly year emissions total emissions per sulphur dioxide dust almost zerothe million chf sales efficient modernised plant cut carbon dioxide emissions tonnes year reduction ofmore business report safety health environmental protection training manuel glauser head corporate safety environment audit team andreas riesen health protection manager basel kaiseraugst sites switzerland talk training roche training group level help embed knowledge throughout group drive awareness company teaching teachers hold conference every two years train seos around world share knowledge employees sites training raise awareness roche representatives use sites also offer goals education programme issues goals key focus years confer interested knowing ence germany participants created local action plans sites support global new recruits introduced procedures goals part induction new employees introduced local training part general induction depart network seos backbone ments right completing computer organisation roche lead organisation based training programme mandatory site company level provide professional new employees new employees asked knowledge tools support range complete checklist help supervisor tailormade training courses classroom colleagues help learn procedures based lectures handson training local specific workplace waste tinually working improve yields addition explore possibilities recycling valorisation chemical waste result pharmaceuticals pro finding customer use waste product duction pose potential risks environ process raw material something else ment disposed responsibly tonnes chemical wastes generated operations generated tonnes ofgeneral incinerated waste compared tonnes inert materials incineration ash slag previous year increase mainly result went landfillthis increase chemical waste construction waste around incinerated around one third primarily rest sent landfilllandfills result increased production waste tamiflu historically used chemical waste besides manufacturing inert materials subject increased monitoring roche assumes responsibility chemical waste originates manufacturing landfill sitewe conduct risk assessment poten processesto reduce type wastewe con tial leakage take preventative actionremedia business report safety health environmental protection tion already completed sites potentially damage ecosystemsin kilo ongoing others grams heavy metals emitted treat mentdown previous year additional tonnes materials paper cardboard glass metals wood plastics roche supports research source impact recycled trace chemicals including pharmaceuticals watercourses environmental risk assessments shown active pharmaceutical ingredients water found watercourses primarily caused normal use inappropriate disposal availability clean water critical roche ourproducts consumersnot pollution manufacture pharmaceuticals diag manufacturing sites nostic products without itthe use biotechnol ogy replacing chemical processes research productionreducing safety risksbut compliance incidents techniques also require greater water use used million cubic metres water committed fully complying rele committed reducing water consump vant laws regulations countries tion local programmes site level well operateour global standards guide efforts improve ecobalance lines take precedence exceed local regu lationsroche received significant sherelated winning idea ecompetition fines incident accident realised roche jacarepagu brazil significant impact people environment cut total water use reusing wastewater reported anywhere roche group cooling systemsaving approximately swiss francs year roche recognises substances used themanufacture ofpharmaceutical products could water consumption million cubic metres potentially misused narcotics toxins chemical weapons regulated chemicals water use used roche small quantitiesunder rig total water use cubic metres orous control compliance applicable per million chf sales legislation contaminated wastewater manufacturing web necessaryprocessed onsite pretreatment plants released public treatment policy guidelines organisational structure plants watercoursessome volatile solvents wwwrochecomsusshe removed treatmentin tonnes position papers organic materials total organic carbon toc wwwrochecomsusshepoliciespositions discharged watercourses treatment policy regulated chemicals decrease significant wwwrochecomsuschemicals reduction partly due detection responsible care reporting major contributor previous wwwrochecomsusresponsiblecare years addition clarecastle site ireland performance data longterm trends definitions made considerable improvements toc wwwrochecomsussheperformance elimination processes small amounts ofheavy metals copperzinc chromium leached piping acidic wastewater biodegradable business report assurance assurance independent assurance report roche nal guidelines definitions procedures estab group sustainability reporting lished prepare report sustainability performance roche corporate sustainability committee roche group responsible subject performed evidencegathering procedures matter evaluation criteria provide assurance sustainability report ing roche consolidated subsidiaries responsibility provide conclusion excluding chugai genentech groupall subject matter based evidencegathering year ended december procedures accordance international standard assurance engagements isae performed evidencegathering proce assurance engagements audits dures hereafter jointly referred subject reviews historical information approved matter december international auditing assurance standards board iaasb key figures tables pages planned performed evidencegathering selected social dimension information procedures obtain basis conclusions social data accordance isae limited reason management reporting processes able assurance engagementwe performed preparation ofthe report figures audit according international standards auditing accordingly express evaluated subject matter audit opinion following criteria evaluation criteria described pages evidencegathering procedures included following work roche group internal sustainability report ing guidelines respect responsible site levelassessing roche staff apply care healthsafety environmental reporting group internal sustainability reporting guidelines published european chemical guidelines well observing compliance industry council cefic sustainability group internal sustainability reporting reporting guidelines published guidelines visiting sample five sites global reporting initiative gri switzerlandswedenpolandand uscover procedures data ing pharmaceuticals diagnostics divi social data preparedcollated aggregated sions internally performing tests sample basis ofthe internal control environment accuracy sustainability reporting system used collect completeness data social data social data group sites data performing specific procedures check sample basisthe data social data accuracy completeness sustainability interviewing responsible stafffor data collec data subject inherent limitations given tion sustainability reporting sites nature methods determiningcalculating visited group level estimating dataour assurance report assessing data consolidation process therefore read connection roches inter group level business report assurance reading performing tests relevant dimension information material respects documentation sample basis including based evaluation criteria group policies management reporting structures documentation systems used based work described reportnothing collectanalyse aggregate reported data come attention causes us believe social data social dimension information dis performing tests sample basis evidence closed sustainability reporting supporting selected data social data give fair picture social perform regard reported data aggregation ance procedures selected sites group level data social dimension information pre pared collated aggregated based however performed site visits established accepted measurement analyt chugai genentech ical methodsin material respectsbased evaluation criteria opinion pricewaterhousecoopers agbasel roche group internal sustainability reporting january guidelines applied properly selected sites internal reporting system group level collect data functioning designed social dimension reporting provides appropriate basis disclosure social dr thomas scheiwiller jrg hutter global reporting initiative report prepared accordance sustainability reporting guidelines gri guidelines represents balanced reasonable presentation organisations report accordance global economicenvironmentaland social performance reporting initiative gri guidelines annual report websitethe gri reviewed report confirms meets accordance criterion details ofhow report indicator found wwwrochecomsusgri franz bhumer business report sales manufacturing overview switzerland croatia argentina czech republic australia denmark austria dominican republic belgium ecuador bermuda el salvador brazil estonia bulgaria finland canada france chile germany china greece colombia guatemala costa rica honduras business report roche global market presence roche global market presence research development services financing toll manufacturing third parties hungary new zealand slovakia india nicaragua slovenia indonesia norway south africa ireland pakistan south korea italy panama spain japan peru sweden latvia philippines taiwan lithuania poland thailand luxembourg portugal turkey malaysia romania united kingdom mexico russia united states morocco serbia uruguay netherlands singapore venezuela business report published cautionary statement regarding forward fhoffmannla roche ltd looking statements baselswitzerland annual report contains certain forwardlook tel ing statements forwardlooking statements fax may identified words believes expects anticipates projects intends media office seeks estimates future similar expressions corporate communications discussion among things strategy baselswitzerland goals plans intentions various factors may tel cause actual results differ materially future fax reflected forwardlooking statements contained annual report among others investor relations pricing product initiatives competitors baselswitzerland legislative regulatory developments tel economic conditions delay inability fax obtaining regulatory approvals bringing prod ucts market fluctuations currency world wide web exchange rates general financial market condi httpwwwrochecom tions uncertainties discovery develop ment marketing new products new uses corporate sustainability committee existing products including without limitation pierre jaccoudchair negative results ofclinical trials research projects tel unexpected side effects pipeline marketed emailpierrejaccoudrochecom products increased government pricing pres sures interruptions production loss order publications orinability obtain adequate protection intel tel lectual property rights litigation loss fax key executives employeesand adverse emailbaselwebmasterrochecom publicity news coverage statement regarding earnings per share growth profit forecast inter preted mean roches earnings earnings per share subsequent period necessarily match exceed historical published earnings earnings per share ofroche next annual general meeting march trademarks mentioned enjoy legal protection roche annual report published german english printed nonchloride bleached paper roche annual report issued f hoffmannla roche ltd basel corporate communications business report